MXPA00008342A - Quinoxalinones as serine protease inhibitors such as factor xa and thrombin - Google Patents

Abstract

This invention discloses quinoxalinones according to Formula (I) or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compositions comprising the compounds, their salts or prodrugs, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.

Description

THE QUINOXALINONES AS INHIBITORS SER1NA PROTEASE OF FACTORS SUCH AS XA AND TROMBINA FIELD OF THE INVENTION In one aspect, the invention describes quinoxalinones that display inhibitory effects on serine proteases such as factor Xa, thrombin and / or factor Vlla. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compositions comprising the compounds, their salts or prodrugs and methods for using them as therapeutic agents for the treatment or prevention of diseases in mammals characterized by abnormal thrombosis.

BACKGROUND OF THE INVENTION In economically developed countries, cardiovascular diseases still represent a major cause of mortality. In particular, abnormal coagulation and inappropriate thrombotic formation in the blood vessels precipitates several acute conditions of cardiovascular diseases. Although it has been recognized that a variety of proteins in plasma such as fibrinogen, serine proteases and cellular receptors are involved in hemostasis, it is the abnormal regulation that has emerged as an important contributing factor for cardiovascular diseases. Thrombin can be considered the main or key regulatory enzyme in the coagulation cascade; it plays a plurinominal role as a regulator of negative and positive feedback in normal hemostasis. However, in some pathological conditions, the former is amplified through the catalytic activation of cofactors required for the generation of thrombin such as factor Xa. Factor Xa, as part of the prothrombinase complex composed of the nonenzymatic cofactor Va, calcium ions and a phospholipid membrane surface regulates the generation of thrombin from its cymogenic prothrombin. In addition, the location of the prothrombinase complex at the convergence of both intrinsic and extrinsic coagulation pathways suggests that inhibition of factor Xa and thus the generation of thrombin may be viable to limit the procoagulant activity of thrombin. In fact, there is ample evidence for the role of factor Xa inhibitors as anticoagulants. Antistasin, a potent inhibitor of blood coagulation factor Xa, from the Mexican sucker: Haementaria officinalis, displays thrombotic activity in several models of venous and arterial thrombosis (Lappato et al., Embo. J., 1997: 5151-5161 ). Other protein or factor Xa polypeptide inhibitors include the recombinant label anticoagulant peptide (rTAP), which is known to accelerate the lysis of the plasminogen activator plasmid medium of recombinant tissue and prevent acute reocclusion in the dog, indicates that factor Xa inhibitors they may be useful as an adjunct to thromboembolic therapy (Mellott et al., Fibrinolysis, 1993: 195-202). Furthermore, in a canine coronary artery, the rTAP model of electrolytic lesion showed that it reduced thrombus mass and occlusion time in the absence of dramatic haemostatic or haemodynamic changes indicating the primary role for factor Xa in the process of arterial thrombosis ( Lynch et al., Thromb Haemostasis, 1995: 640-645; Schaffer et al., Circulation, 1991: 1741-1748). On the venous side, rTAP was also shown to reduce fibrin deposition in a model of venous thrombosis in a rabbit and to have little effect on systemic hemostatic parameters (Fioravanti et al., Thromb. Res., 1993: 317-324). In addition to the fact that these relatively high molecular weight proteins are not suitable as oral antithrombotic agents, there are also examples of low molecular weight factor Xa inhibitors. In particular, DX9065a, a synthetic low molecular weight factor Xa inhibitor, has also demonstrated antithrombotic potential in several models in rats with experimental thrombosis. In both models of venous ecstasy and arteriovenous shunt, inhibition of thrombus formation was achieved at doses that had little effect on APTT, indicating that DX9065a is effective in the prevention of thrombosis and therefore has antithrombotic therapeutic potential Wong et al., Thromb. Res., 1996: 117-126). Most of the factor Xa inhibitors known to date have previously been summarized in two reviews (Edmunds et al., Annual Reports in Medicinal Chemistry, 1996: 51 and Kunitada and Nagahara, Curr. Pharm. Des., 1996: 531- 542). However, it is readily apparent that there is still a need for more effective agents that regulate the proteolytic activity of factor Xa. Some quinoxalinones have been reported and these compounds have displayed marked pharmacological activity: Japanese Application: JP 88-99097 880421; Japanese Application: JP 89-254348 890929; CAN 1 6: 83686; World Publication 9707116; Otomasu et al., Yakugaku Zasshi, 1970; 90 (11): 1391-1395; Seth M et al., Indian J. Chem., 1974; 12 (2): 124-1288; Japanese Patent 63145272; Sparatore el al., Fármaco, 1989; 44 (10): 945-950 and F. Hahn et al., Arch. Int. Pharmacodyn. Ther., 1992: 108. None of the aforementioned articles describe or suggest compounds of Formula I that are inhibitors of the serine proteases involved in the blood coagulation cascade.

SUMMARY OF THE INVENTION An object of the present invention is to provide inhibitors of serine protease that display inhibitory activity towards the enzymes involved in the coagulation cascade and mainly the white enzymes, factor Xa, thrombin and factor Vlla. A further object of the present invention is to provide inhibitors of serine proteases that display inhibitory activity towards the factor Xa of the target enzyme and are provided in a pharmaceutically acceptable state. In addition, a further object of the present invention is to provide the use of these factor Xa inhibitors and formulations thereof as anticoagulants and factor Xa inhibitors. Yet, a further object of the present invention is to provide the use of these factor Xa inhibitors and formulations thereof for the therapeutic treatment of various thrombotic diseases. A further object of the present invention is a process for the synthesis of these low molecular weight thrombin inhibitors. The enzyme inhibitors of the present invention are included by the structure of the general Formula I shown below.

The present invention meets these objectives and provides novel compounds that display antithrombotic activity. More specifically, the present invention provides novel compounds that display antithrombotic activity via the inhibition of factor Xa as reflected in Formula I, or pharmaceutically acceptable salts or prodrug forms thereof. The present invention also provides acceptable pharmaceutical compositions comprising the novel compounds or their salts or prodrug forms and methods of use as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis. Therefore, in a first embodiment, the present invention provides novel compounds of Formula I: or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein: A is selected from N, Nalkyl, NCH2, N (alkyl) CH2, CH2N, CH2N (alkyl), NO; B is selected from H, (C3-2o) alkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heteroalkylalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, each optionally substituted with Ri and R2; D is selected from H, (C3-2o) alkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heteroalkylalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, each optionally substituted with Ri and R2; E is absent or selected from O, S, NH; F is selected from N, NCH2, CH2N; G is absent or selected from alkyl, alkyl interrupted by one or more heteroatoms, cycloalkyl, cycloalkyl interrupted by one or more heteroatoms; J is absent or is selected from aryl or heterocycle each optionally substituted with Ri and R2; K is absent or selected from an alkyl, alkyl interrupted by one or more heteroatoms, cycloalkyl interrupted by one or more heteroatoms, cycloalkylalkyl interrupted by one or more heteroatoms, each optionally substituted with Ri and R2. L is selected from H, chloro, fluoro, bromo, iodo, OH, O (alkyl), amine, alkyl, fluoroalkyl, amide, NO2, SH, S (O) n (alkyl), SO3H, alkyl SO3, aldehyde, ketone , Acid, Ester, Urea, Oalkylamide, O-alkyl ester, O-alkyl acid, N-alkyl acid, alkylamine, alkylamide, alkyl ketone, alkyl acid, alkyl ester, alkylurea, N-alkylamide, N-alkyl ester, alkyl NC (= 0), aryl NC (= 0), nitrile, cycloalkyl NC ( = O), cycloalkylalkyl NC (= O), alkylaryl NC (= O), Ri, R2; Ri is selected from H, amine, alkylamine, amide, C (= NH) NHNH2, alkylC (= NH) NHNH2, C (= NH) NHOH, alkylC (= NH) NHOH, NHC (= NH) NH2, alkyl NHC ( = NH) NH2, C (= S) NH2, alkylC (= S) NH2, alkyl C (= NH), alkylC (= NH) alkyl, C (= NR3) N (R4) (R5), alkylC (= NR3 ) N (R4) (R5); R 2 is selected from H, chloro, fluoro, bromo, iodo, OH, Oalkyl, amine, alkylaldehyde, alkylamide, alkyl ester, alkyl ketone, alkyl acid, O-alkylamide, O-alkyl acid, alkyl-ester, aminalkyl acid, aminalkylamide, aminalkyl ester, alkyl NC (= O), aryl NC (= O), cycloalkyl NC (= O), alkylaryl NC (= 0), alkylamine, amide, aldehyde, ester, ketone, NO2, SH, S (O) n (C? -alkyl?), SO3H, alkyl SO3, CHO, acid, alkyl, alkyl C (= NH), C (= NH) NHNH2, alkylC (= NH) NHNH2, C (= NH) NHOH, alkylC (= NH) NHOH, NHC (= NH) NH2, alkylNHC (= NH) NH2, C (= S) NH2, alkylC (= S) NH2, alkylC (= NH) alkyl, C (= NR3 ) N (R4) (R5), alkylC (= NR3) N (R4) (R5); R3, R4 and R5 are a hydrogen atom, an alkyl group having 1 to 4 carbon atoms optionally interrupted by a heteroatom or R4 and R5 are linked to form - (CH2) pW- (CH2) q-, wherein p and q are an integer 2 or 3, a certain position in the methylene chain is substituted or unsubstituted by an alkyl group having 1 to 4 carbon atoms, W is a direct bond, -CH2-, -O -, -N (Rd) - or -S (0) r wherein R6 is H or alkyl and r is O or 1 or 2; n is selected from 0, 1, 2; Xi is C or N; X2 is C or N; X3 is C or N; X4 is C or N and - represent an additional optional bond when A is N. Preferred compounds according to this invention have the Formula II: or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein A, B, E, G, J, K and L are as defined above. Another preferred group of compounds having Formula III: or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein A is N or Nalkyl and B, G, J, K, L and - are as defined above. Even more preferred compounds have Formula IV: or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein G, J, K, L, Ri and - are as defined above. The most preferred compounds provided by this invention are compounds of Formula V: or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein X, Y, R, R8 and - are as follows: X is selected from (CH2) s, (CH2) 4, (CH_) 6, CH2C (= O) NHCH2CH2, (CH2) 2NH (CH2) 2, CeH4, CH2C6H4, C6H4CH2, CßHio, CH2CH = CHCH2CH2Y is selected from 2,6-dimethylpiperidinyl, piperidinyl, 2,2,6,6-tetramethyl-piperidinyl-4-one, (2-carboxy) piperidinyl, (3-carboxy) piperidinyl, (4-carboxy) piperidinyl, 3,5-dimethylpiperidinyl, (4-hydroxy) piperidinyl, (2-amino) piperidinyl, piperidin-4-one -yl, (2-dimethylaminomethyl) -piperidinyl, (4-D-methylamino) -piperidinyl, (4-sulfonyloxy) -piperidinyl, (2-phenyl) piperidinyl, 2,5-dimethylpyrrolidinyl, pyrrolidinyl, (2-carboxy) pyrrolidinyl, (3-N-acetyl-N-methyl) pyrrolidinyl, (3-amino) pyrrolidinyl, (2,5-bis-methoxymethyl) -pyrrolidinyl, 2-hydroxymethyl-pyrrolidinyl, 2-hydroxymethyl-5-methyl-pyrrolidinyl, diisopropylamino, dimethylamino, diethylamino, methylamino, 1-methyl-4,5-dihydro-1 H-imidazol-2-yl, 2,5-dimethyl-1 HA-imidazolyl, morpholinyl, 2,6-dimethylmorpholinyl, piperazinyl, 2,6-dimethylpiperazinyl, 1 H-pyrazolyl, tetrahydro-1H-pyrazolyl and 2,5-dimethyltetrahydro-1 H-1 -pyrazolyl; R7 is selected from (3-amidino) phenyl, (3-hydroxy) phenyl, [3-hydroxylamino (imino) methyl] -phenyl, [3-hydrazino (imnino) methyl] -phenyl, (3-aminomethyl) phenyl , (3-amino) phenyl, (3-methylamino) phenyl, (3-dimethylamino) phenyl, (5-amidino-2-hydroxyl) phenyl, (1 -amidino) piperid-3-yl, (1 - amidino) pyrrolid-3-yl, (5-amidino) thien-2-yl, (5-amidino) furan-2-yl, (5-amidino) -1, 3-oxazol-2-yl, (2-amidino) ) -1, 3-oxazol-5-yl, 1 H -pyrazol-5-yl, tetrahydro-1 H -pyrazol-3-yl, (1 -amidino) tetrahydro-1 H -pyrazol-3-yl, (2 -amidino) -1 H-imidazol-4-yl, (2-amino) -1 H -imidazol-4-yl, (5-amidino) -1 H -imidazol-2-yl, (5-amino) -1 H-imidazol-2-yl, pyridin-3-yl, (4-amino) pyridin-3-yl, (4-dimethylamino) pyridin-3-yl, (6-amino) pyridin-2-yl, (6-amidino) pyridin-2-yl, (2-amino) pyridin-4-yl, (2-amidino) pyridin-4-yl, (2-amidino) pyrimid-4-yl, (2-amino) pyrimidin-4-yl, (4-amidino) pyrimid-2-yl, (4-amino) pyrimidin-2-yl, (6-amidino) pyrazin-2-yl, (6-amino) pyrazin-2-i, (4-amidino) -1, 3,5-triazin-2-yl, (4-amino) -1, 3,5-triazin-2-yl, (3-amidino) -1, 2,4-triazin-5-yl, (3-amino) -1, 2,4-triazin-5-yl, (3-amidino) benzyl, (3-amino) benzyl, (3-aminomethyl) benzyl, (1 -amidino) piperid-3-ylmethyl, (1 -amidino) pyrrolid-3-ylmethyl, (5-amidino) thien-2-ylmethyl, (5-amidino) furan-2-ilmetl, (5-amidino) oxazol-2-ylmethyl, (2-amidino) imidazol-5-ylmethyl, (5-amidino) imidazol-2-ylmethyl, (6-amidino) pyridin-2-ylmethyl, (6-amino) ) pyridin-2-ylmethyl, (2-amidino) pyrimidin-4-ylmethyl, (2-amino) pyrimidin-4-ylmethyl, (4-amidin) pyrimidin-2-ylmethyl, (4-amino) pyrimidin-2-ylmethyl, (6-amidino) pyrazin- 2-ylmethyl, (6-amino) pyrazin-2-ylmethyl, 3-aminociclohexil, 3-amidinociclohexil, 3-aminociclohexilmetil, 3-amidinociclohexilmetil, 3-aminociclopentil, 3-amidinociclopentil, 3-aminociclopentylmetil and 3-amidinociclopentylmetil and selects of H, Cl, F, SH, SMe, CF3, CH3, CO2H, CO2Me, CN, C (= NH) NH2, C (= NH) NHOH, C (= NH) NHNH2, C (= 0) NH2, CH2OH, CH2NH2, NO2, OH, OMe, OCH2PI-1, OCH2CO2H, O (CH2) 2CO2H, O (CH2) 3CO2H, NHCH2CO2H, NH (CH2) 2COH, NH (CH2) 3CO2H, OCH2CH2OH, OCH2 (1 H-tetrazol-5-yl), NH2, NHButil, NMe2, NHPh, NHCH2Ph, NHC (= O) Me, NHC (= O) c-Hexyl, NHC (= O) CH2c-Hexyl, NHC (= 0) Ph, NHC (= O) CH2Ph, NHS (= O) 2Me, NHS (= O) 2c-HexyI, NHS (= O) 2CH2c-Hexyl, NHS (= O) 2Ph and NHS (= O) CH2Ph; In one embodiment of Formula V, Y, R7 and Re are as defined above and Y is (CH2) 5. In another embodiment of Formula V, X, R7 and R8 are as defined above and Y is 2,6-dimethylpiperidinyl. In another embodiment of Formula V, X, Y and Rs are as defined above and R is (5-amidino-2-hydroxy) phenyl. In another embodiment of Formula V, X, Y and R are as defined above and R8 is H. In another embodiment of Formula V, R is as defined above and X is (CH2) s, Y is 2.6 -dimethylpiperidinyl and Rs is H. In another embodiment of Formula V, R7 is as defined above and X is (CH2) 5, Y is 2,5-dimethylpyrrolidinyl and Rs is H. Representative compounds of the present invention include: 3- (4-5 - [(2f?, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxaline l) benzenecarboxylamide; 1-5 - [(2R> 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3- (3-hydroxy-phenyl) -2 (7 - /) - quinoxalinone; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -? / - hydroxybenzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidohydrazide; 3- [3- (Aminomethyl) phenyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-2 (W) -quinoxalinone; 3- (3-Aminophenyl) -1-5 [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 / -) -pyridinyl] pentyl-2 (/?) - quinoxalinone; 1-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3- [3- (methylamino) phenyl] -2 (7 - /) - quinoxalinone; 3- [3- (Dimethylamino) phenyl] -1-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (7 - /) - quinoxalonone; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxaliniI) -4-hydroxybenzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-d, 2-drono-2-quinoxalinyl) tetrahydro -1 (2H) -pyridinecarboximidamide; 3- (4-5 - [(2R / 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1-pyrrolidinecarboximidamide; 5- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -2-thiophenecarboxamidamide; - (4-5 - [(2R, 6S) -2,6-D'metltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -2- furancarboximidamide; 2- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl ) -1, 3-oxazole-5-carboximidamide; 5- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1, 3-oxazole-2-carboximidamide; 1-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3- (1H-pyrazol-3-yl) -2 (1 H) -quinoxalinone; 1 -5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-tetrahydro-1 H -pyrazol-3-yl-2 (7 - /) - quinoxalinone; 3- (4-5 - [(2R 6S) -2,6-D'metltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1-pyrazolidinecarboximide gives; 5- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1H-imidazole- 2-carboximidamide; 3- (2-Amino-1H-imidazol-5-yl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2,7) -pyridinyl] pentyl-2 (1 - / ) -quinoxalinone; 2- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / l /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxaliniI) -1H -dazole-5-carboximidamide; 3- (5-Amino-1 H-imidazol-2-yl) -1 -5 - [(2R / 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 H) -quinoxalinone; 1-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2f7 /) - pyridinyl] pentyl-3- (3-pyridinyl) -2 (1H) -quinoxalinone; 3- (6-Am.no-3-pyridinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 -) -quinoxalinone; 3- [6- (D-methylamino) -3-pyridinyl] -1-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2 / - /) - r pyridinyl] pentyl-2 (1r7) -quinoxalinone; 3- (6-Amino-2-pyridinyl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 / - /) - quinoxalinone; 6- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -2-pyridinecarboximidamide; 3- (2-Amino-4-pyridinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 H) -quinoxalinone; 4- (4-5 - [(2R; 6S) -2,6-D-methyltetrahydro-1 (2ry) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) - 2-pyridinecarboximidamide; 4- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -2- pyrimidinecarboximidamide; 3- (2-Amino-4-pyrimidinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2f7y) -pyridinyl] pentyl-2 (1H) -quinoxalinone; 2- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2ft ') - pyridinium] pentiol-3-oxo-1,2-dihydro-2-quinoxalinyl) -4-pyrimidinecarboxyramide; 3- (4-Amino-2-pyrimidinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-2 (1 H) -quinoxalinone; 6- (4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2 / -) -pyridinyl] pentyl-3-oxo-3,4-d-hydroxy-2-quinoxalinyl) - 2-prazrazecarboximidamide; 3- (6-Amino-2-pyrazinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 - /) - quinoxalinone; 4- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1, 3, 5-triazine-2-carboxamidedamide; 3- (4-Amino) -1, 3,5-triazin-2-yl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 / - /) - quinoxalinone; 5- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1, 2,4-triazine-3-carboximidamide; 3- (3-Amino-1, 2,4-triazin-5-yl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 ( 1 / - /) - quinoxalinone; 3 - [(4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2 / L /) - pyridinyl] pentyl-3-oxo-3,4-dihydro -3-quinoxalinyl) methyl] benzenecarboximidamide; 3- (3-Aminobenzyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2r) -pyridinyl] pentyl-2 (1 H) -quinoxalinone; 3- [3- (Aminomethyl) benzyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 ^ 2 H; -pyridinyl] pentyl-2 (1H) -quinoxalinone; 3 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] tetrahydro- 1 (2 / - /) - pyridinecarboximidamide; 3 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r »') - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -1 pyrrolidinecarboximidamide; 5 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2rt ') - pyridinyl] pentiol-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl ] -2-thiophenecarboxamidamide; 5 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7,) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] - 2-furancarboximidamide; 2 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -1, 3 -oxazole-5-carboximidamide; - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -1H-imidazole -2-carboximidamide; 2 - [(4-5 - [(2R, 6S) -2,6-D] methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -1- -imidazole-5-carboxylamide; 6 - [(4-5 - [(2R; 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -2-pyrid Nacarboximidamide; 3 - [(6-Amino-2-pyridinyl) methyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 / - /) - quinoxalinone; 4 - [(4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2 -) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl ) methyl] -2-pyrimidinecarboximidamide; 3 - [(2-Amino-4-pyrimidinyl) methyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-2 (1 / - /) - quinoxalinone; 2 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) meth] -4-pyrimidinecarboxamidedamide; 3 - [(4-Amino-2-pyrimidinyl) methyl] -1 -5 - [(2R, f5S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 - /) - quinoxalinone; 6 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentl-3-oxo-3,4-dihydro-2 -quinoxalinyl) methyl] -2-pyrazinecarboximidamide; 3 - [(6-Amino-2-pyrazinyl) methyl] -1-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 / - /) -quinoxalinone; 3- (3-Aminocyclohexyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 ('2 / -0-pyridinyl] pentyl-2 (1 H) -quinoxalinone; 5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2-r7) -pyridinyl] -tert-3-oxo-3,4-dihydro-2-quinoxalinyl) -cyclohexanecarboximidamide; 3 - [(3-Aminocyclohexyl) methyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1H) -quinoxalinone; 3 - [(4-5 - [(2R, 6S) -2I6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] cyclohexanecarboximidamide; 3- (3-Aminocyclopentyl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1H) -quinoxalinone; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / - /) - pyridinyl] penti-3-oxo-3,4-dihydro- 2-quinoxalinyl) cyclopentanecarboxamidamide; 3 - [(3-Aminocyclopentyl) methyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 H) -quinoxalinone; 3 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] cyclopentanecarboximidamide; 3- (4-4 - [(2R, 6S) -2,6-D'metltetrahydro-1 (2H) -pyridinyl] butyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-6 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] hexyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 2- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2r7) -quinoxalinyl] -? / - 2 - [(2R 6S) -2,6-d.methyltetrahydrate -1 (2 - /) - pyridinyl] ethylacetamide; 3- [3-3- [Amino (imn) methyl] phenyl-2-oxo-1 (2H) -quinolalinyl] - / V - [(2R; 6S) -2,6-dimethyltetrahydro- 1 (2H) -pyridinyl] methylpropanamide; 3-4- [2- (2 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] ethylamino) etl] -3-oxo-3,4-dihydro -2-quinoxalinylbenzenecarboximidamide; 3- [4- (2-2 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] ethoxyethyl] -3-oxo-3,4-dihydro-2-quinoxalinyl-benzenecarboximidamide; 3- (4-4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] phenyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-4 - [(2R, 6S) -2,6-D'metltetrahydro-1 (2r7) -pyridinyl] benzyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarbox Midamide; 3- [4 -. (4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] methylphenyl) -3-oxo-3,4-dihydro-2-quinoxaIinyl] benzenecarboximidamide; 3- (4-4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] cyclohexyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- [4- (4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] cyclohexylmethyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- [4- (4 - [(2R, 6S) -2,6-D-methyl-tetrahydro-1 (2-r7) -pyridinyl] methyl-cyclohexyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] -benzenecarboximide gives; 3- (4-3 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] cyclopentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboxyramide; 3- [4- (3 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] cyclopentylmethyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- [4- (3 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] methicyclopentyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- (4- (E) -5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2 - /) - pyridinyl] -2-pentenyl-3-oxo-3,4- dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- [3-Oxo-4- (5-piperidinopentyl) -3,4-dihydro-2-quinoxalinylj-benzenecarboximidamide; 3-3-Oxo-4- [5- (2,2,6,6-tetramethylpiperidino) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 1 -5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2 / - /) -quinoloxalinyl] pentyl-2-piperidinecarboxylic acid; acid-1-5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2 - /) - quinoxalinyl] pentyl-3-piperidinecarboxylic acid; acid-1-5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2 H) -quinoxalinyl] pentyl-4-piperidinecarboxylic acid; 3-4- [5- (3,5-Dimethylpiperidino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (4-Hydroxypiperidino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (2-lminopiperidino) pentyl-3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-3-Oxo-4- [5- (4-oxopiperidino) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [4- (5-2 - [(Dimethylamino) methyl] piperidinopentyl) -3-oxo-3,4-dihydro-2-quinoxalinylj-benzenecarboximidamide; 3- (4-5- [4- (D-methylamino) piperidino] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; acid-1-5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2 / - /) - quinoxalinyl] pentyl-4-piperidinesulfonic; 3-3-Oxo-4- [5- (2-phenylpiperidino) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (2,5-Dimethyl-1-pyrrolidinyl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-3-Oxo-4- [5- (1-pyrrolidinyl) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; acid-1-5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2-r7) -quinoxalinyl] pentyl-2-pyrrolidinecarboxylic acid; ? / - (1-5- [3-3- [Amino (imino) meth]] phenyl-2-oxo-1 (2 / - /) - quinolinyl] pentyltetrahydro-1 - / - pyrrole-3- il) -N-methylacetamide; 3-4- [5- (3-Amino-1-pyrrolidinyl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- (4-5- [2,5-bis (Methoxymethyl) -1-pyrrolidinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5- [2- (Hydroxymethyl) -1-pyrrolidinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5- [2- (Hydroxymethyl) -5-methyl-1-pyrrolidinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3-4- [5- (Diisopropylamino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (Diethylamino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (Methylamino) pentyl-3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (1-methyl-1 H-imidazol-2-yl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (2,5-Dimethyl-1H-imidazol-1-yl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [4- (5-Morpholinopentyl) -3-oxo-3,4-dihydro-2-quinoxalinyl-benzenecarboximidamide; 3-4- [5- (3,5-Dimethylmorpholino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [3-oxo-4- (5-piperazinopentyl) -3,4-dihydro-2-quinoxalinylj-benzenecarboximidamide; 3-4- [5- (2,6-Dimethyl-piperazino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinyl-benzenecarboximidamide; 3-3-Oxo-4- [5- (1 H -pyrazol-1 -yl) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [3-Oxo-4- (5-tetrahydro-1H-pyrazol-1-ylpentyl) -3,4-dihydro-2-quinoxalinyl-benzenecarboximidamide; 3-4- [5- (2,5-Dimethyltetrahydro-1H-pyrazol-1-yl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- (6-Chloro-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2ry) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R 6S) -2,6-D-methyltetrahydro-1 (2H) -pyridinyl] penti-6-fluoro-3-oxo-3, 4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-6-sulfanyl-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- [4-5 - [(2R, 6S) -2,6-D-methyl-tetrahydro-1 (2-r7) -pyridinyl] -pentyl-6- (methylsulfanyl) -3-oxo-3,4-dihydro-2-quinoxalinyl ] benzenecarboximidamide; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2?) - pyridinyl] pentyl-3-oxo-6- (trifluoromethyl) -3,4-dihydro-2- quinoxalinyl] benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-6-methyl-3-oxo-3,4-dihydro- 2-quinoxalinyl) benzenecarboximidamide; acid-2-3- [Amino (methyl) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3- oxo-3,4-dihydro-6-quinoxalcarboxylic acid; Methyl 2-3- [amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro- 6-quinoxalinecarboxylate; 3- (6-Cyano-4-5 - [(2R, 6S) -2,6-d'metltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxal Nl) benzenecarboxymeramide; 2-3- [Amino (imino) meth] phenyl-4-5 - [(2R / r3S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro -6-quinoxalinecarboximidamide; 2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] phenyl- / Hydroxy- 3-oxo-3,4-dihydro-6-quinoxalinecarboximidamide; 3-4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6- [hydrazino (imine) methyl] -3-oxo-3,4-dihydro-2- Quinoxalinylbenzenecarboximidamide; 2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-3,4- dihydro-6-quinoxalinecarboxamide; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-6- (hydroxymethyl) -3-oxo-3,4-dihydro-2-quinoxalinyl ] benzenecarboximidamide; 3- (6- (Aminomethyl) -4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R / 6S) -2,6-Dimethyltetrahydro-1 (2f7) -pyridinyl] pentyl-6-nitro-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6-hydroxy-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6-methoxy-3-oxo-3,4-dihydro-2-quinoxalinyl ) benzenecarboximidamide; 3- (6- (Benzyloxy) -4-5 - [(2R, f5S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-qu Noxalinyl) benzenecarboxyramide; acid-2 - [(2-3- [Amino (1-methyl) methyl] phenyl-4-5 - [(2R, 6S) -2,6-d-methyl-tetrahydro-1 (2 / - /) - pyridinyl ] pentyl-3-oxo-3,4-dihydro-6-quinoxaliniI) oxy] -acetic; acid-3 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3 , 4-dihydro-6-quinoxalinyl) oxy] -propanoic acid; acid-4 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R / 6S) -2,6-dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl-3 -oxo-3,4-dihydro-6-quinoxalinyl) oxy] -butanoic acid; acid-2 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3 -oxo-3,4-dihydro-6-quinoxalinyl) amino] -acetic; acid-3 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, r3S) -2,6-d-methytetrahydro-1 (2rt ') - pyridine l] pentyl-3-oxo-3,4-dihydro-6-quinoxalinyl) amino] -propane; acid-4 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - / '(' 2R, 6S; -2,6-dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-6-quinoxalinyl) amino] -butanoic; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-6- (2-hydroxyethoxy) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentiol-3-oxo-6- (1 H-1,2,3I4-tetraazol-5-methoxy) -3,4-dhydro-2-quinoxalinyl] benzenecarboximidamide; Amino-4-5 - [(2R, 6S) -2,6-d.methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (6- (Butylamino) -4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarbox Myridamide; 3- (6- (Dimethylamino) -4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro- 2-quinoxalinyl) benzenecarboxymethyldane; 3- (6-Anilino-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4 -dihydro-2-quinoxalinyl) benzenecarboxyramide; 3- (6- (B enzyminolamino) -4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R 6S) -2,6-dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4- dihydro-6-quinoxalinyl) acetamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentl-3 -oxo-3,4-dihydro-6-quinoxalinyl) cyclohexanecarboxamide; ? - (2-3- [Amino (im!) -methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3- oxo-3,4-dihydro-6-quinoxalinyl) -2-cyclohexylacetamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R / 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4 -dihydro-6-quinoxalinyl) benzenecarboxamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, f3S) -2,6-dimethyltetrahydro-1 (2 / -) -pyridinyl] pentyl-3-oxo-3 , 4-dihydro-6-quinoxalyl) -2-phenylacetamide; 3-4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2H) -pyridinyl] pentyl-6 - [(methylsulfonyl) amino] -3-oxo-3,4-dihydro-2 -quinoxalinylbenzenecarboximidamide; 3- (6 - [(Cyclohexylsulfonyl) amino] -4-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro- 2-quinoxalinyl) benzenecarboximidamide; 3- (6 - [(Cyclohexylmethyl) sulfonyl] amino-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4 -dihydro-2-quinoxalinyl) benzenecarboximidamide; 7-Chloro-1- (3-dimethylamino-propyl) -3-phenyl-1 H-quinoxalin-2-one; 7-Chloro-1- (3-dimethylaminopropyl) -3-phenyl-1H-quinoxalin-2-one; 3- (4-Chloro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 2 (1 H) -Quinoxalinone, 7-methoxy-1,3-bis (p-methoxyphenyl); 3- (3-Chloro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 3- (4-Fluoro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 3- (3,4-Dichloro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 1- (2-Diethylamino-ethyl) -4-oxy-3-phenyl-1 H-quinoxalin-2-one; 1 - . 1 - (2-Diethylamino-ethyl) -4-oxy-3-phenyl-1 H-quinoxalin-2-one; 3- (2-Chloro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 3- (4-Bromo-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 2 (1 - /) - Quinoxalinone, 7-methoxy-1- (p-methoxyphenyl) -3-phenyl; 7-Methoxy-1- (4-methoxy-phenyl) -3- (4-trifluoromethyl-phenyl) -1H-quinoxalin-2-one; 2 (1H) -Quinoxalinone, 1-methyl-3-phenyl-, 4-oxide; 7-Methoxy-1- (4-methoxy-phenyl) -3- (3-trifluoromethyl-phenyl) -1H-quinoxalin-2-one; 7-Methoxy-1 - (4-methoxy-f in i I) -3-p-tol il-1 H-quinoxalin-2-one; 3- (2-Fluoro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 1- (3-Diethylamino-propyl) -3-phenyl-1 H-quinoxalin-2-one; 7-Hydroxy-1- (4-hydroxy-phenyl) -3-phenyl-1 H-quinoxalin-2-one; 3- (4-Chloro-phenyl) -1-phenyl-1 H-quinoxalin-2-one; 2 (1 H) -Quinoxalinone, 1,3-diphenyl; 1 - [5- (2,6-Dimethyl-piperidin-1-yl) -pentyl] -3-phenyl-1 H-quinoxalin-2-one; 3-. { 4- [5- (2,6-Dimethyl-piperidin-1-yl) -pentyl] -1-methyl-3-oxo-1, 2,3,4-tetrahydro-quinoxalin-2-yl} -N-hydroxy-benzamidine; 3-. { 4- [5- (2,6-Dimethyl-piperidin-1-yl) -pentyl] -3-oxo-3,4-dihydro-quinoxalin-2-yl} -N-hydroxy-benzamide; 3- (3-Amino-1 H -indazol-5-yl) -1 - [5- (2,6-dimethyl-piperidin-1-yl) -pentyl] -1H-quinoxalin-2-one; 2 (1H /) - Quinoxalinone, 1 - [2- (diethylamino) ethyl] -3 - [[4- (methoxy) phenyl] methyl]; 3-4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-6 - [(phenylsulfonyl) amino] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide and 3- (6 - [(Benzylsulfonyl) amino] -4-5 - [(2R 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2- quinoxalinyl) benzenecarboxylamide.

DETAILED DESCRIPTION OF THE INVENTION The term "alkyl" means a long and branched unsaturated or saturated carbon chain having from 1 to 20 carbon atoms. Typical alkyl groups include methyl, isobutyl, pentyl, 2-methyl-pentyl, pent-1,4-dienyl, but-1-enyl, and the like. The term "cycloalkyl" means an unsaturated or saturated carbon chain that forms a ring having from 3 to 20 carbon atoms. Typical examples include cyclopropyl, cyclohexyl and the like. The term "cycloalkylalkyl" means a cycloalkyl group bonded to an alkyl group wherein "cycloalkyl" and "alkyl" are as defined above and include, for example, cyclopropylmethyl, cyclopentylethyl and the like. The term "heteroalkyl" means a long and branched unsaturated or saturated carbon chain having from 1 to 20 carbon atoms wherein one or more carbon atoms is replaced by a heteroatom selected from oxygen, nitrogen, sulfur, sulfoxide or sulfone. Typical "heteroalkyl" groups include methoxymethyl, 3-thiomethylpropyl and 2-thiomethoxyethoxymethyl and the like. The term "aryl" represents an unsaturated carbocyclic ring (s) of 6 to 16 carbon atoms which is optionally substituted by OH, O (alkyl), SH, S (alkyl), amine , halogen, acid, ester, amide, alkyl ketone, aldehyde, nitrile, fluoroalkyl, nitro, sulfone, sulfoxide or alkyl (Ci-β). Typical rings include phenyl, naphthyl, phenanthryl and anthracenyl. Preferred aryl rings are phenyl, substituted phenyl and naphthyl. The term "arylalkyl" means an aromatic radical linked to an alkyl radical wherein "aryl" and "alkyl" are as defined above and include, for example, benzyl and naphthylmethyl. The term "heterocycle" means a saturated or unsaturated monocyclic or unsaturated ring (e.g., bicyclic) incorporating one or more heteroatoms (e.g., 1-4) selected from N, O, and S. It is understood that a heterocycle is optionally substituted with OH, O (alkyl), SH, S (alkyl), amine, halogen, acid, ester, amide, alkyl ketone, aldehyde, nitrile, fluoroalkyl, nitro, sulfone, sulfoxide or alkyl Ci-β- Examples of appropriate monocyclic heterocycles include, but are not limited to thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, piperidinyl, pyrrolidinyl, piperazinyl, acetidinyl, aziridinyl, morpholinyl, thietanil, oyetanil substituted or unsubstituted. Monodiheterocycles include but are not limited to 2- or 3-thienyl; 2- or 3-furanyl; 1-, 2- or 3-pyrrolyl; 1-, 2-, 4- or 5-imidazolyl; 1-, 3-, 4- or 5-pyrazolyl; 2-, 4- or 5-thiazolyl; 3-, 4- or 5-isothiazolyl; 2-, 4- or 5-oxazolyl; 3-, 4- or 5-isoxazolyl; 1, 3- 5-triazolyl; 1-, 2- or 3-tetrazolyl; 2, 3- or 4-pyridinyl; 2-pyrazinyl; 2-, 4- or 5-pyrimidinyl; 1-, 2-, 3- or 4-piperidinyl; 1-, 2- or 3-pyrrolidinyl; 1- or 2-piperazinyl; 1-, 2- or 3-acetidinyl; 1- or 2-aziridinyl; 2-, 3- or 4-morpholinyl; 2- or 3-tietanil; 2- or 3-oxetanyl. Examples of suitable bicyclic heterocycles include but are not limited to indolizinyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl and preferably 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl; 1-, 2-, 3-, 5-, 6-, 7- or 8-indolizinil; 1-, 2-, 3-, 4-, 5-, 6- or 7-isoindolyl; 2-, 3-, 4-, 5-, 6- or 7-benzothienyl; 2-, 4-, 5-, 6- or 7-benzoxazolyl; 1-, 2-, 4-, 5-, 6- or 7-benzimidazolyl; 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl; 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl. The term "heteroatom" as used herein represents oxygen, nitrogen or sulfur (O, N or S) as well as sulfoxyl or sulfonyl (SO or SO2) unless otherwise indicated. It is understood that the alkyl chains interrupted by one or more heteroatoms mean that a carbon atom of the chain is replaced with a heteroatom having the appropriate valence. Preferably, an alkyl chain is interrupted by 1 to 4 heteroatoms and that two adjacent carbon atoms are not replaced. Examples of such groups include methoxymethyl, 3-thiomethylpropyl and 2-thiomethoxyethoxymethyl. The term "amine" refers to a group such as NH2, NHalkyl, NH (cycloalkyl), NH (cycloalkylalkyl), NH (aryl), NH (arylalkyl), NH (heteroaryl), NH (heteroarylalkyl), N (alkyl) (alkyl), N (alkyl) (cycloalkyl), N (alquiIo) (cicloaIquilalquiIo), N (alkyl) (aryl), N (alkyl) (aryl), N (alkyl) (heteroaryl), N (alkyl) (heteroarylalkyl ), N (cycloalkyl) (cycloalkyl), N (cycloalkyl) (cycloalkylalkyl), N (cycloalkyl) (aryl), N (cycloalkyl) (arylalkyl), N (cycloalkyl) (heteroaryl), N (cycloalkyl) (heteroarylalkyl), N (cycloalkylalkyl) (cycloalkylalkyl), N (cycloalkylalkyl) (aryl), N (cycloalkylalkyl) (arylalkyl), N (cycloalkylalkyl) (heteroaryl), N (cycloalkylalkyl) (heteroarylalkyl), N (aryl) (cycloalkylalkyl ), N (aryl) (aryl), N (aryl) (arylalkyl), N (aryl) (heteroaryl), N (aryl) (heteroarylalkyl), N (arylalkyl) (arylalkyl), N (arylalkyl) (heteroaryl) ), N (arylalkyl) (heteroarylalkyl), N (heteroaryl) (heteroaryl), N (heteroaryl) (heter oarylalkyl), N (heteroarylalkyl) (heteroarylalkyl). The term "acid" refers to C (= O) OH. The term "ketone" refers to alkyl C (= O), cycloalkyl C (= O), cycloalkylalkyl C (= O), aryl C (= O), arylalkyl C (= 0), heteroaryl C (= 0), heteroarylalkyl C (= 0). The term "ester" refers to a group such as C (= 0) Oalkyl, C (= O) Ocloalkyl, C (= O) Ocloalkylalkyl, C (= O) aryl, C (= O) Oarylalkyl, C (= O) Otero-heteroaryl, C (= O) -heteroarylalkyl. The term "amide" refers to a group such as C (= 0) NH2, C (= O) NHalkyl, C (= O) NH (cycloalkyl), C (= O) NH (cycloalkylalkyl), C (= O) ) NH (aryl), C (= O) NH (arylalkyl), C (= O) NH (heteroaryl), C (= 0) NH (heteroarylalkyl), C (= 0) N (alkyl) (alkyl), C (= 0) N (alkyl) (cycloalkyl), C (= 0) N (alkyl) (cycloalkyl) alkyl, C (= 0) N (alkyl) (aryl), C (= O) N (alkyl) (arylalkyl), C (= O) N (alkyl) (heteroaryl), C (= O) N (alkyl) (heteroarylalkyl), C (= O) N (cycloalkyl) (cycloalkyl), C (= O) ) N (cycloalkyl) (cycloalkylalkyl), C (= O) N (cycloalkyl) (aryl), C (= 0) N (cycloalkyl) (arylalkyl), C (= 0) N (cycloalkyl) (heteroaryl), C ( = 0) N (cycloalkyl) (heteroarylalkyl), C (= O) N (cycloalkylalkyl) (cicloalquilaIquilo), C (= O) N (cycloalkylalkyl) (aryl), C (= O) N (cicloaIqu¡Ialquilo) (ar lalquilo), C (= O) N (cycloalkylalkyl) (heteroar¡lo), C (= 0) N (c¡cloalquilalquilo) (heteroarylalkyl), C (= 0) N (aryl) (cicloalqu¡lalquilo), C (= 0) N (aryl) (aryl). C (= O) N (aryl) (arylalkyl), C (= O) N (aryl) (heteroaryl), C (= 0) N (aryl) (heteroarylalkyl), C (= 0) N (arylalkyl) (arylalkyl), C (= 0) N (aryllalkyl) (heteroaryl), C (= 0) N (arylalkyl) (heteroarylalkyl), C (= O) N (heteroaryl) (heteroaryl), C (= O) N (heteroaryl) (heteroarylalkyl), C (= O) N (heteroarylalkyl) (heteroarylalkyl). The term "urea" refers to a group such as NHC (= O) N (alkyl) (alkyl), NHC (= 0) N (alkyl) (cycloalkyl), NHC (= 0) N (alkyl) ( cycloalkylalkyl), NHC (= 0) N (alkyl) (aryl), NHC (= 0) N (alkyl) (arylalkyl), NHC (= O) N (alkyl) (heteroaryl), NHC (= O) N (alkyl ) (heteroarylalkyl), NHC (= O) N (cycloalkyl) (cycloalkyl), NHC (= O) N (cicIoalquilo) (cycloalkylalkyl), NHC (= O) N (cycloalkyl) (aryl), NHC (= O) N (cycloalkyl) (arylalkyl), NHC (= O) N (cycloalkyl) (heteroaryl), NHC (= O) N (cycloalkyl) (heteroarylalkyl), NHC (= O) N (cycloalkylalkyl) (cycloalkylalkyl), NHC (= 0 ) N (cycloalkylalkyl) (aryl), NHC (= 0) N (cycloalkylalkyl) (arylalkyl), NHC (= 0) N (cycloalkylalkyl) (heteroaryl), NHC (= O) N (cycloalkylalkyl) (heteroarylalkyl) ), NHC (= O) N (aryl) (cycloalkylalkyl), NHC (= O) N (aryl) (aryl), NHC (= O) N (aryl) (arylalkyl), NHC (= 0) N (aryl) (heteroaryl), NHC (= O) N (aryl) (heteroarylalkyl), NHC (= 0) N (arylalkyl) (arylalkyl), NHC (= 0) N (arylalkyl) (heteroaryl), NHC (= O) N ( Arylalkyl) (heteroarylalkyl) o), NHC (= O) N (heteroaryl) (heteroaryl), NHC (= O) N (heteroaryl) (heteroarylalkyl), NHC (= O) N (heteroarylalkyl) (heteroarylalkyl). The term "halogen" refers to chlorine, fluorine, bromine and iodine.

The highlighted or triangular arrows are only a representation of a stereochemical descriptor. All stereoisomers including the enantiomers and diastomers are included in Formulas I through V and are provided in this invention. When specific isomers are drawn, they are the preferred isomers. In some situations, the compounds may exist as tautomers. All tautomers are included in Formulas I through V and are provided in this invention. When the compounds are administered, some metabolic change may occur. All metabolites are included in Formulas I to V and are provided in this invention. When a link to a substitute is shown to cross the link by connecting 2 atoms in a ring, then said substitute can be linked to any atom in the ring, provided that the atom will accept the substitute without violating its valence. When several atoms of the substitute are bound to the ring atom, then it is the first atom of the listed substitutes that is attached to the ring. When a bond is represented by a line such as "-", it means that the link may be absent or present on condition that the resulting compound is stable and of satisfactory valence. The compounds of the present invention are capable of forming acid addition salts (see for example, Berge S.M et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977: 1-10) with inorganic acids such as, example, hydrochloric acid, sulfuric acid and the like as well as salts derived from organic acids such as, for example, aliphatic or aliphatic mono- and dicarboxylic acids and aromatic sulfonic acids. The acid addition salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt. The free base form can be regenerated by contacting the salt form with a base. While the free base may differ more from the salt form in terms of physical properties, such as solubility, the salts are equivalent to their respective free bases for the purposes of the present invention. Certain compounds of the present invention can exist in unsolvated form as well as in solvated form including the hydrated form. In general, the solvated form including the hydrated form are equivalent to the unsolvated form and are included within the scope of the present invention. The "prodrugs" include any covalently linked carrier that releases the active drug origin in vivo in accordance with Formulas I to V. Examples of prodrugs include acetates, formats, benzoate derived from alcohols and amines present in the compounds of Formulas I to V They also include derivatives of amidine or guanine functionality and would include C (= NR3) NH2 wherein R3 is selected from OH, NH2, C1-4 alkoxy, C ar-aryloxy, CMO alkoxycarbonyl, C ar-io aryloxycarbonyl. Preferred derivatives include examples wherein R3 is OH, NH2, methoxy and ethoxycarbonyl. The following table provides a list of the abbreviations and definitions thereof, used in the present invention.

Abbreviation Description AMC aminomethylcoumarin aPTT activated partial thromboplastin time BOC butyloxycarbonyl-tertiary BOP-benzotriazole-1-yloxy-tris (dimethylamino) phosphomethyl hexafluorophosphate BZ benzoate CDCI3 deuterochloroform DMF dimethyl formamide DMSO dimethyl sulfoxide 1H-NMR proton nuclear magnetic resonance HCl chloride hydrogen HF hydrogen fluoride HMPA hexamethylphosphoramide HPLC high pressure liquid chromatography MOT medium occlusion time MS (APCI) mass spectrometry (atmospheric pressure Cl) MS (Cl) mass spectrometry (chemical ionization) MS (ES) mass spectrometry (electro spray) NaOH sodium hydroxide nBuLi n-butyl lithium NH4CI ammonium chloride Pd / C palladium on carbon PtO2 platinum oxide r.t. or RT ambient temperature TFA trifluoroacetic acid THF tetrahydrofuran TT thrombin time VAZO-52 2, 2'-azobis-2-methylvaleronitrile A method for preventing and treating chronic, subacute and acute thrombotic diseases in a mammal comprising administering to said mammal an effective amount of a compound of Formulas I to V is also provided in this invention. The compounds are useful as anticoagulants for the treatment and prophylaxis of diseases such as arterial and venous thrombosis, pulmonary embolism and ischemic events such as myocardial infarction or cerebral infarction. These compounds also have therapeutic utility for the prevention and treatment of complications of resident vascular access ports and arteriovenous shunts and coagulopathies associated with cardiopulmonary bypass or other extracorporeal systems. These compounds are useful for the prevention or treatment of unstable angina, refractory angina of intermittent claudication, disseminated intravascular coagulation and ocular accumulation of fibrin. Since thrombin and serine proteases have also been shown to activate a number of different cell types, these compounds are useful for the treatment or prophylaxis of septic shock and other inflammatory responses such as chronic or acute arteriosclerosis. The compounds also have utility in the treatment of neoplasia / metastasis and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. In a preferred method, the thrombotic disease is selected from venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, angina, cancer and diabetes. A further embodiment of this invention is a pharmaceutical formulation comprising a compound of Formulas I to V administered with a diluent, excipient or carrier thereof.

Preparation of the Compounds of the Invention The compounds of Formulas I to V can be prepared by any of the methods known to those skilled in the art of organic chemistry. The following general schemes represent the preferred routes to provide the compounds of this disclosure. Reactions are typically carried out in solvents appropriate to the reagents and substrates used. It is understood that the functionality present in the molecule must be compatible with the reactants and the proposed reaction conditions. Not all compounds of Formulas I to V fall within a given class, they may be compatible with some of the reaction conditions described. Such restrictions are readily apparent to those skilled in the art of organic synthesis and subsequently alternative methods should be used. The compounds of the present invention can be prepared by various synthetic sequences. A preferred route is shown in Scheme 1.

Scheme 1 Step a: The ortho-phenylenediamine is treated with an appropriately substituted bromoacetic acid derivative, such as 2-bromo-2- (3-bromophenyl) acetic acid, in a basic medium, such as aqueous sodium hydroxide, which upon heating at 60 ° C and subsequently maintained at this temperature for 30 minutes produces the product 3- (3-bromophenyl) -1,2,3,4-tetrahydro-2-quinoxalinone as a precipitate.

Step b: Simply treating tetrahydroisoquinoline with an oxidant, such as dichloro dicyanobenzoquinone (DDQ) or lead tetracetate and heating in toluene produces the product 3- (3-bromophenyl) -1,2-dihydro-2-quinoxalinone, which can be purified by, for example, recrystallization.

Step c: Bromine aryl is converted to the corresponding nitrile by, for example, treatment with cupric cyanide in a solvent such as DMF. Typically, the reaction mixture is heated to 160 ° C and maintained at this temperature for several hours, typically 12, to produce the required product. Alternatively, the bromine or iodine or triflate are converted to the nitrile by treatment with a transition metal, such as triphenylphosphine tetrakis of palladium and zinc cyanide. The mixture is then heated in a solvent such as DMF, typically at a temperature of 80 ° C for several hours or until the reaction is judged complete, for example by TLC.

Step d: Alkylation is typically achieved by treatment with a suitable electrophile and by addition of a base in a dipolar aprotic solvent. Typical conditions include, for example, use of a bis-electrophilic substrate such as 1,5-dibromopentane in a dipolar aprotic solvent such as DMF or DMSO and addition of a base, such as sodium hydride. Alternatively, alkylation can be achieved by the addition of a transfer reagent phase such as benzyltriethylammonium chloride and using a base such as sodium ethoxide. Reaction rates are typically improved by application of heat and therefore, the reactions run from 0 ° C to 70 ° C.

Step e: Treatment of an amine, such as cis-2,6-dimethylpiperidine at an elevated temperature such as 50 ° C produces the expected alkylated N-piperidine. The amine can be used as a solvent or alternatively, the amine can be added in stoichiometric proportions and the reaction mixture refluxed in a solvent such as ethanol, acetonitrile or toluene. The product, such as the appropriate acid addition salt, is subsequently neutralized by addition of the base such as aqueous potassium hydroxide and isolated by extraction with an organic solvent such as ethylacetate.

Step f: The conversion of nitrile to hydroxyamidine is achieved by allowing the nitrile to react with hydroxylamine in methanol at room temperature. Typically, hydroxylamine hydrochloride is added to the nitrile containing substrate at room temperature and the reaction is initiated by the addition of the base such as potassium carbonate or d soopropylethylamine.

Step g: Amidoxin can be reduced directly, but is typically activated by adding acetic anhydride trifluoroacetic anhydride to produce the intermediate, O-acylated or O-trifluoroacetyl, which can be isolated or alternatively used directly in the subsequent reduction step. The steps g and h can be combined, for example, the reduction with Pd / C is carried out in acetic anhydride / acetic acid or trifluoroacetic anhydride / trifluoroacetic acid.

Step h: The substrate was dissolved in methanol or acetic acid or trifluoroacetic acid and treated with a transition metal catalyst such as Palladium dispersed in carbon and subsequently briefly hydrogen, typically for 1 to 12 hours at 50 psi, in a solvent such as methanol or ethanol. The product is subsequently isolated by crystallization or via chromatography such as reverse phase HPLC.

An alternate procedure for the preparation of compounds of Formula I involves what is shown in Scheme 2, similar to the method of M.C. Aiamanni Fármaco, Ed. Sci., 1981; 36 (5): 359 and Ahmad A.R., Tetrahedron 199551 (47): 12899-12910.

Scheme 2 Step a: The treatment of [N-5- (2,6-d.methylpiperidyl) pentyl] -orto-phenylene diamine with methyl 2- (3-cyanophenyl) -2-oxoacetate in, for example, ethanol produces quinoxalinone expected Steps b and c: Similar to the procedure described in Scheme 1, the nitrile is converted to the corresponding amidine. An alternative procedure for preparing compounds of Formula I is shown in Scheme 3.

Scheme 3 Step a: The treatment of (2-aminophenyl) methylamine with 2-bromo-2- (3-cyanophenyl) acetic acid, by the route of the specific example, produces quinoxalinone. Typically, the reaction is carried out in the presence of aqueous base with the application of external heating so that the reaction mixture is maintained at a temperature of about 60 ° C for several hours, typically two hours. In favorable situations, the product is precipitated directly from the reaction mixture. The product can also be isolated by extraction of the reaction mixture with ethylacetate and the required regioisomer is isolated by crystallization or silica gel chromatography. The predominant regioisomer is as expected.

Step b: The intermediate is subsequently alkylated with, for example, 1- (5-bromopentyl) -2,6-dimethylpiperidine by treatment of the quinoxalinone with sodium hydride in a solvent such as DMF from 0 ° C to 50 ° C. Accordingly, the N-regioisomers against O are separated by chromatography. Alternatively, 1,5-dibromopentane can be used in excess and the N-alkyl-bromine required to be isolated by chromatography. A separate step is subsequently required to convert the bromine to, for example, 2,6-dimethylpiperidine. This transformation is achieved by heating the bromine in natural 2,6-dimethylpiperidine, typically around 80 ° C.

Step c: The final stage involves the conversion of nitrile to amidine and can therefore be carried out by the process described above by the route of an amidoxime intermediate or by treatment of the nitrile with anhydrous hydrogen chloride in an alcohol solvent, such as methanol to produce the intermediate methyl ether. This intermediate is subsequently treated with a source of ammonia, such as ammonium acetate to produce the required amidine.

The substituted alpha-bromo phenylacetates used in these reactions are prepared by various standard procedures, such as, for example, those shown in Scheme 4.

Scheme 4 Step a: The acetic acid derivatives are prepared by converting the substituted benzoic acid to the corresponding acid chloride with, for example, oxalyl chloride and catalytic DMF and subsequently treated with ethereal diazomethane.

Step b: Rearrangement with silver oxide in an alcohol solvent, such as methanol, produces the homologated methyl acetic ester acid.

Step c: The functionality of the alpha position is subsequently achieved by refluxing a solution of the ester in carbon tetrachloride with N-bromosuccinimide in the presence of a radical initiator such as AIBN. An alternative procedure involves the treatment of the acetic acid derivatives with bromine in the presence of phosphorus tribromide which will produce the phenyl-alphabromo acetate in a typical manner according to the Hell-Volhard-Zelinskii reaction. Alternatively, the alpha bromo ester intermediate can be prepared by the procedure shown in Scheme 5.

Scheme 5 Br Stage a: In this situation the aldehyde, such as 3-bromobenzaldehyde as a representative example, reacts with malonitrile in the presence of piperidine in a solvent such as dioxane to produce 2 - [(3-bromophenyl) methylene] malonitrile.

Step b: Epoxide formation proceeds rapidly with commercial discoloration at a pH of 5 to 6.

Step c: Treatment with hydrobromic acid in methanol yields the required methyl 2-bromo-2- (3-bromophenyl) acetate; alternatively, the use of hydrobromic acid in the absence of an alcoholic solvent produces the corresponding acid derivative.

Alternative procedures for the conversion of nitriles to amidines are also available. The treatment of the nitrile with hydrogen chloride in an alcoholic solvent produces the corresponding methylmerchloride. These intermediates are subsequently treated with a source of ammonia, for example, ammonia in methanol or ammonium chloride or ammonium acetate and the mixture is stirred and heated, if necessary, to produce the amidine. Nitriles, in turn, are available by, for example, a palladium-cross-linked reaction catalyzed by Zn (CN) 2.

Scheme 6 demonstrates that another method can be used to prepare the compounds of the invention and is similar to that reported by Holley et al. J. Amer. Chem. Soc., 1952, 74, 5445-5448 and Kirt et al. J. Org. Chem., 1969, 34, 395.

Scheme 6 Step a: In this situation a natural or unnatural amino acid, such as L-phenylalanine or 2-amino-2- [2- (benzyloxy) -5-cyanophenyl] acetic acid is combined with an ortho fluoronitrobenzene in a solvent such as ethanol with an additional base such as sodium bicarbonate and the mixture is heated. Advantageously, the nitro benzene substrate is substituted in the para position with a fluorine substituent, with for example a carbomethoxy substituent so that the addition reaction with an amino acid (or peptide derivative) can proceed at a lower temperature.

Step b: The reduction of the nitro substituent to produce an aniline intermediate can proceed by the hydrogenation route on a transition metal catalyst such as palladium in carbon in a solvent such as water or base (for example sodium bicarbonate). Subsequently, the rapid intramolecular cyclization proceeds in neutralization to produce the required 3,4-dihydro-quinoxalinone intermediate.

Step c: Treatment of the dihydroquinoxalinone with an oxidant such as DDQ produces the quinoxalinone intermediate, which can then be processed as described in scheme 1 to produce, for example, the desired factor Xa inhibitors such as 3- (4-5). - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -4-hydroxybenzenecarboximidamide.

The compounds of the present invention are further characterized by their ability to inhibit the catalytic activity of factor Xa, which is demonstrated in the following tests. The compounds of the present invention can be prepared by tests by dissolving them in a stabilizer to give solutions whose concentrations vary from 1 to 100 μM. In a test to determine the inhibitory dissociation constant, K, for a given compound, a fluorogenic or chromogenic substrate of factor Xa will be added to a solution containing a test compound and factor Xa; the catalytic activity resulting from the enzyme was determined spectrophotometrically. This test is well known to those skilled in the art and is commonly used to determine antithrombotic activity. The compounds of the present invention can be used as anticoagulants in vitro or ex vivo as in the case of activation by contact with foreign thrombogenic surfaces, as found in the channeling used in extracorporeal deviations. The compounds of the invention can be used to cover the surface of said thrombogenic ducts. For this purpose, the compounds of the invention can be prepared as lyophilized powders, redissolved in an isotonic saline solution or a similar diluent and added in an amount sufficient to maintain the blood in an anticoagulated state. The therapeutic agents of the present invention can be administered alone or in combination with pharmaceutically acceptable carriers. The proportion of each carrier is determined by the solubility and chemical nature of the compound, the route of administration and standard pharmaceutical practice. For example, the compounds can be injected parenterally, either intramuscularly, intravenously or subcutaneously. For parenteral administration, the compound can be used in the form of sterile solutions containing other solutes, for example, enough saline or glucose to make the solution isotonic. The compounds can be administered orally in the form of tablets, capsules or granules containing suitable excipients such as starch, lactose, white sugar and the like. The compounds may also be administered sublingually in the form of troches or lozenges in which each active ingredient is mixed with sugar or corn syrup, flavoring and coloring agents and subsequently dehydrated sufficiently to make the appropriate mixture to compress it into a solid form. The compounds may be administered orally in the form of solutions which may contain flavoring and / or coloring agents. Typical formulations will contain from about 5 to 95 weight percent of a compound of the invention. The amount of the compound of the invention to be used to prevent and treat thrombotic diseases is that amount which is effective to prevent or treat the condition without causing unacceptable side effects. Such effective amounts will be from about 0.01 mg / kg to about 500 mg / kg, preferably from about 1 mg / kg to about 100 mg / kg. The doctors will determine the precise doses of the therapeutic agents present that are the most appropriate. The doses may vary according to the route of administration and the particular compound selected. In addition, the doses may vary with the particular patient being treated. When the composition is administered orally, typically a greater amount of the active agent will be required to produce the same effect as that caused with a minor amount provided parenterally. To further assist in the understanding of the present invention, the following non-limiting examples of said factor Xa inhibitor compounds are provided. The following examples, of course, should not be construed as specifically limiting the present invention, variations currently known or further developed, are within the scope of one skilled in the art and considered to fall within the scope of the present invention as described. in this document. Preferred compounds of the present invention are synthesized using conventional preparation steps and recovery methods known to those skilled in the art of organic and bio-organic synthesis, because they provide a new and unique combination for the complete synthesis of each compound. The preferred synthetic routes for intermediates involved in the synthesis, as well as the resulting anti-thrombotic compounds of the present invention are the following.

EXAMPLES In general, the evaporation of the reaction mixtures was carried out by rotary evaporation under vacuum at room temperature of 18 ° C to 25 ° C or at elevated temperatures above 50 ° C. Chromatography, preferably by liquid chromatography under pressure average, it was usually performed in Merck Kieselgel. The reverse phase purification via high pressure liquid chromatography (HPLC), for particular polar compounds, was carried out in C-18 reverse phase silica gel using an elution gradient of water and acetonitrile containing 0.1% trifluoroacetic acid. The final products displayed mass spectrum and nuclear magnetic resonance (NMR) spectrum consistent with their assigned structure. Intermediates were not fully characterized and their purity was routinely determined by HPLC or thin layer chromatography.

EXAMPLE 1 3- [3- (Amidino) phenyl] -1-. { 5 - [(2?, 6 S) -2,6-dimethylhexahydro-1-pyridinyl] pentyl} -1, 2-dihydro-2-quinoxalinone Step (a): Preparation of 3- (3-Bromophenyl) -1,2,3,4-tetrahydro-2-quinoxalinone 2-Bromo-2- (3-bromophenyl) acetic acid (4.95 g, 16.9 mmol) was added to an aqueous solution (40 ml) of sodium hydroxide (0.67 g, 16.8 mmol). Ortho-phenylenediamine (1.82 g, 16.9 mmol) was added and the mixture was transferred to an oil bath at 60 ° C. After 30 minutes, the solid that had separated was collected, washed with water and then dried under empty. Recrystallization from ethanol and water produced the required product (2). (APCI MS) 303 and 305. Anal. Ci4HnN2O? Br ?: Found: C, 55.27; H, 3.45; N, 8.94. Required: C, 55.47; H, 3.66; N, 9.24. 1 H NMR (DMSO, 400 MHz): d 10.47 (1 H, s), 7.51 (1 H, s), 7.46 (1 H, d, J = 7.7 Hz), 7.28 (2 H, m), 6.8-6.6 (3 H , m), 6.60 (1 H, m) 4.96 (1 H, s) Step (b): Preparation of 3- (3-Bromophenyl) -1,2-dihydro-2-quinoxalinone To (2) (1.73g, 5.7 mmol) in toluene (50 ml) was added 2,3-dichloro-5,6-dicyano-, 4-benzoquinone. { DDQ} (1.30 g, 5.7 mmol). The mixture was refluxed for 3 hours, cooled and subsequently filtered. This solid was triturated with ethanol to analytically produce the pure product (3) (1.14 g, 66%). (APCI MS) 301 and 303. Anal. C? 4H9N2O? Br ?: Found: C, 55.96; H, 2.88; N, 9.15. Required: C, 55.84; H, 3.01; N, 9.30. 1 H NMR (DMSO, 300 MHz): d 12.62 (1 H, s), 8.46 (1 H, m), 8.27 (1 H, d, J = 7.8 Hz), 7.80 (1 H, d, J = 8.0 Hz ), 7.66 (1 H, m), 7.44 (1 H, m), 7.40 (1 H, m), 7.29 (2 H, m).

Step (c): Preparation of 3- (3-Cyanophenyl) -1,2-d-hydroxy-2-quinoxalinone To quinoxalinone (3) (0.581 g, 1.93 mmol) in DMF (4 ml) was added copper cyanide (1) (0.343 g, 3.82 mmol) and the mixture was heated under nitrogen in a sealed tube at 160 ° C. 12 hours. The mixture was cooled, diluted with ethyl acetate (50 ml) and washed with aqueous ammonium hydroxide (2 x 10 ml). After washing with brine, the organic phase was dried over magnesium sulfate and then evaporated in vacuo to yield (4) (0.316 g, 66%). 1 H NMR (DMSO, 300 MHz): d 8.76 (1 H, brs), 8.27 (1 H, dt, J = 8.4 Hz), 7.95 (1 H, d, J = 7.9 Hz), 7.82 (1 H, d , J = 7.0 Hz), 7.69 (1 H, t, J = 8.1 Hz), 7.51 (1 H, t, J = 1.3 Hz), 7.24 (2 H, m).

Step (d): Preparation of 1- [5-Bromopentyl] -3- (3-cyanophenyl) -1,2-dihydro-2-quinoxalinone To (4) (0.39 g, 1.58 mmol) in DMF (3 ml) was added sodium hydride (60% in oil, 0.070 g, 1.75 mmol) and subsequently 1,5-dibromopentane (0.65 ml, 3 equiv.). The mixture was stirred at 0 ° C for 6 hours, diluted with water (20 ml) and then extracted into ethyl acetate (100 ml). After it was washed with brine and dried over magnesium sulfate, the product (5) (0.287 g, 46%) was isolated by silica gel chromatography, eluent of 80% hexane in ethyl acetate (a minor polar compound: it was also isolated 2 - [(5-bromopentyl) oxy] -3- (3-cyanophenyl) quinoxaline (0.179 g, 29%)). 1 H NMR (DMSO, 300 MHz): d 8.64 (1 H, m), 8.53 (1 H, dt, J = 8.0 Hz), 7.99 (1 H, dt, J = 7.8 Hz), 7.93 (1 H, dt , J = 7.8 Hz), 7.68 (3H, m), 7.40 (1 H, m), 4.30 (2H, t, J = 7.3 Hz), 3.54 (2H, t, J = 6.8 Hz), 1.87 (2H, m), 1.71 (2H, m), 1.52 (2H, m).

Step (e): Preparation of 3- [3- (Cyano) phenyl] -1-. { 5 - [(2R, 6S) -2,6-dimethylhexahydro-1-pyridinyl] pentyl} -1, 2-dihydro-2-quinoxalinone To (5) (0.285 g, 072 mmol) was added cis-2,6-dimethylpiperidine (5 ml), and subsequently the mixture was heated at 50 ° C for 16 hours. The mixture was evaporated in vacuo to produce the required product (6) sufficiently pure for subsequent reactions. (APCI MS) 428.

Step (f): Preparation of 3- [3- (Amidino) phenyl] -1-. { 5- (2R) 6S) -2J6-dimethylhexahydro-1-pyridinyl] pentyl} -1,2-dihydro-2-quinoxalinone To (6) (0.10 g, 0.24 mmol) in ethanol (5 mL) was added hydroxylamine hydrochloride (0.164 g, 2.36 mmol) and then diisopropylethylamine (0.4 mL, 2.30 mmol). The mixture was stirred at room temperature for 16 hours and then extracted into ethyl acetate (50 ml) from hydroxide (5 ml). After washing with brine, the intermediate amidoxime was isolated by evaporation in vacuo. This process produces 0.08 g of intermediate, HPLC: RT = 9.27 min. (Beckman 235328 C-18 - μm 4.6 mm x 25 cm, eluted with a mixture of solvents consisting of (i) 0.1% trifluoroacetic acid in water and (ii) trifluoroacetic acid in acetonitrile, gradient profile 80:20 (i) : (¡) At 10:90 (i) :( ii) in 23 minutes, flow rate 1.5 ml / minute,? = 214 nM). (MS APCI) 461. The amidoxime (0.08 g) was dissolved in acetic acid (1 ml) and treated with acetic anhydride (5 ml). After 1 hour, the mixture was evaporated in vacuo to yield the acetylated intermediate 0.09 g, HPLC: RT = 11.79 min. (Beckman 235328 C-18 5 μm 4.6 mm x 25 cm, eluted with a solvent mixture consisting of (i) 0.1% trifluoroacetic acid in water and (ii) trifluoroacetic acid in acetonitrile, gradient profile 80:20 (i) : (ii) at 10:90 (i) :( ii) in 23 minutes, flow rate 1.5 ml / minute,? = 214 nM). Tridluoroacetic acid (5 ml) was added to the acetylated intermediate (0.09 g) and subsequently palladium in charcoal (20%) (0.04 g) was added. The mixture was evacuated and subsequently a hydrogen balloon was attached. After 16, the mixture was filtered, evaporated and purified by reverse phase HPLC (Vydac 218TP 1022 C-18, eluted with a mixture of solvents consisting of (i) 0.1% trifluoroacetic acid in water and (ii) trifluoroacetic acid at 0.1% in acetonitrile, gradient profile 95: 5 (¡) :( i¡) to 60:40 (¡) :( ii) in 90 minutes, flow rate 20 ml / minute,? = 214 nM) and lyophilized to give 23 mg of the product (7) as a solid / oil. 1 H NMR (DMSO, 300 MHz): d 10.4 (1 H, bs), 9.36 (2 H, d, J = 11.1 Hz), 9.10 (1 H, brs), 8.57 (1 H, d, J = 7.7 HZ) , 8.19 (1 H, bs), 8.12 (1 H, dt, J = 7.9 Hz), 7.91 (1 H, t, J = 7.3 Hz), 7.8-7.6 (4H, m), 3.99 (2H, t, J = 7.0 Hz), 3.40 (2H, brd), 3.02 (2H, m), 2.80 (2H, m), 1.98-1.4 (16H, m). HPLC: RT = 8.49 min. (Beckman 235328 C-18 5 μm 4.6 mm x 25 cm, eluted with a solvent mixture consisting of (i) 0.1% trifluoroacetic acid in water and (i) 0.1% trifluoroacetic acid in acetonitrile, gradient profile 80: 20 (¡) :( i) at 10:90 (i) :( ii) in 23 minutes, flow rate 1.5 ml / minute,? = 214 nM).

EXAMPLE 2 3- (4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -4- hydroxybenzenecarboximidamide Stage (a): Preparation of 2- (benzyloxy) -5-bromobenzenecarbaldehyde -Bromosalicylaldehyde (8) (100 g, 496 mmol) was dissolved in EtOH (300 ml) and a solution of KOH (27.8 g, 496 mmol) in H2O (80 ml) was added. After stirring at room temperature for 30 min, benzyl bromide (71.2 ml, 596 mmol) was added, which was previously passed through a neutral alumina sealant. The resulting mixture was heated to reflux for 18 hours, during which time a colorless precipitate formed. After cooling to room temperature, H20 (50 ml) was added and the main compound was filtered. After washing with H2O the main compound (9) was recrystallized from EtOH to give 122 g (85%) of a colorless solid. 1 H NMR (400 MHz, CDCl 3) 10.46 (d, 1 H); 7.90 (d, 1 H); 7.56 (dd, 1H); 7.30 (m, 5H); 6.91 (d, 1H); 5.14 (s, 2H). MS 292 (M +), 261 (M-CHO) HPLC 20.45 min. (95% H2O: CH3CN) + 0.1% TFA (10% H2O: 90% CH3CN) + 0.1% TFA for 22 min in a Cya Vyadec 218TP54 Column.

Step (b): Preparation of 2- [2- (benzyloxy) -5-bromophenyl] -2-hydroxyacetonitrile 2- (benzyloxy) -5-bromobenzenecarbaldehyde (9) (20 g, 69 mmol) was dissolved in MeOH (150 ml) and subsequently followed by the addition of potassium cyanide (20.1 g, 308 mmol). Acetic acid (6.3 ml, 109 mmol) was added dropwise at room temperature for 20 minutes. The resulting mixture was stirred for an additional hour. Acetic acid (2 ml) was added and the mixture was diluted with H2O (60 ml). After concentration under reduced pressure, the aqueous residue was extracted with EtOAc (3 x 100 ml). The organic blenders were washed with brine and dried over MgSO 4. Filtration and concentration left a pale yellow oil, which was without further purification. The main compound (10) could be isolated in pure form by column chromatography gradient (10% EtOAc in Hexanes). 1 H NMR (400 MHz, CDCl 3) 7.53 (d, 1 H); 7.24 (m, 6H); 6. 86 (d, 1H); 5.52 (d, 1H); 5.13 (s, 2H); 3.38 (d, 1H). MS 199, 201 (M-Bn-CN). HPLC 20.40 min. (95% H2O: 5% CH3CN) + 0.1% TFA (10% H2O: 90% CH3CN) + 0.1% TFA for 22 minutes in a Column C? 8 Vyadec 218TP54.

Step (c): Preparation of methyl 2- [2- (Benzyloxy) -5-bromophenyl] -2-hydroxyacetate 11 2- [2- (Benzyloxy) -5-bromophenyl] -2-hydroxyacetonitrile crude (10), from the above, was dissolved in anhydrous dioxane (25 ml), ether (25 ml) and MeOH (6 ml). After cooling the mixture to 0 ° C, it was saturated with HCl gas and warmed to room temperature. A formed precipitate and the mixture were stirred for 1.5 h. [If the mixture became too viscous to stir, anhydrous ether was added]. The reaction mixture was diluted with ether (200 ml) and filtered. The colorless solid was washed with ether and used as such. The solid was suspended in H2O (60 ml) and dioxane (60 ml) and stirred vigorously for approximately 4 h. The reaction was completed when all the solids had disappeared and an oil residue remained. The mixture was poured into H2O (150 mL) and extracted with EtOAc (3 x 100 mL). The combined organics were washed with brine and dried over MgSO4. Filtration and concentration yielded the crude primary compound, which was used without purification. . The main compound (11) could be isolated in pure form by column chromatography (15% EtOAc in Hexanes). 1 H NMR (400 MHz, CDCl 3) 7.4 (m, 7 H), 6.82 (m, 1 H), 5.32 (d, 1 H), 5.90 (ABq, 2 H), 3.70 (s, 3 H), 3.63 (d, 2 H) ). MS 352 (M +). HPLC 17.5 min. (H2O 95%: CH3CN 5%) + TFA 0.1% a (H2O 10%: CH3CN 90%) + TFA 0.1% for 22 min in a Column Cis Vyadec 218TP54.

Step (d): Preparation of methyl 2- [2- (Benzyloxy) -5-bromophenyl] -2-oxoacetate 11 12 Dimethyl sulfoxide (12.4 ml, 164 mmol) was added slowly to a solution of oxalyl chloride (7.2 ml, 82.4 mmol) in CH 2 Cl 2 (100 ml) at -78 ° C. After the addition the mixture was stirred at -78 ° C. C for 15 min. A solution of methyl 2- [2- (Benzyloxy) -5-bromophenyl] -2-hydroxyacetate (11) (68.6 mmol) in CH 2 Cl 2 (60 mL) was added via a cannula. After the mixture was stirred for 30 min at -78 ° C, triethylamine (47.8 ml, 343 mmol) was added and the mixture was allowed to warm to room temperature. After stirring the mixture for 1 hour at room temperature, it was poured into H2O (200 ml). The layers were separated and the aqueous layer was washed with EtOAc (3x100 ml). The combined organics were washed with brine and dried over MgSO 4. After concentration, compound (12) was recrystallized from EtOAc / Hexanes to yield 13.5 g (60% aldehyde) as a colorless solid. 1 H NMR (400 MHz, CDCl 3) 7.99 (d, 1 H); 7.65 (dd, 1 H); 7.40 (m, 5H); 6.95 (d, 1 H); 5.06 (s, 2H); 3.34 (s, 3H). MS 256, 258 (M +). HPLC 22.6 min. (95% H2O: 5% CH3CN) + 0.1% TFA (10% H2O: 90% CH3CN) + 0.1% TFA for 22 min on a C? 8 Vyadec 218TP54 column.

Step (e): Preparation of 3- [2- (benzyloxy) -5-3-phenylphenyl] -2 (f.) -quinolone 12 13 Methyl 2- [2- (benzyloxy) -5-bromophenyl] -2 (1 H) -quinoxalinone (12) (7.0 g, 20 mmol) was dissolved in MeOH (60 ml) and 1,2-phenylenediamine (2.2 g) was added. 20 mmol). The mixture was heated to reflux overnight, a precipitate formed at that time. The mixture was cooled to room temperature and H2O (10 ml) was added. The product was filtered and washed with a small amount of cold MeOH to yield 7.7 g (94%) of the main product (13) as a colorless solid. 1 H NMR (400 MHz, DMSO) 12.54 (s, 1 H); 7.73 (d, 1 H), 7.65 (m, 2H); 7.23 (m, 8H); 7.10 (d, 1 H); 5.08 (s, 2H). MS 407, 409 (M +). HPLC 24.1 min (H2O 95%: CH3CN 5%) + TFA 0.1% a (H O 10%: CH3CN 90%) + TFA 0.1% for 22 min in a Column Cie Vyadec 218TP54.

Step (f): Preparation of 4- (Benzyloxy) -3- (3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarbonitrile 13 14 3- [2- (Benzyloxy) -5-bromophenyl] -2 (7 - /) - quinoxalinone (13) (20.4 g, 50 mmol) was dissolved in anhydrous DMF (200 ml) and subsequently Zn (CN) 2 was added (3.52 g, 30 mmol) and Pd (Ph3P) 4 (5.78 g, 5 mmol). The resulting mixture was heated at 100 ° C for 5h. The dark green solution was cooled to room temperature and stirred overnight. The main product (14) formed as a precipitate, which was separated by filtration and washed with ether. Produced 12.3 g 69%. 1 H NMR (400 MHz, DMSO) 12.63 (s, 1H); 7.92 (dd, 1H); 7.87 (d, 1 H); 7.79 (d, 1 H); 7.58 (m, 1 H); 7.2-7.4 (m, 8H); 5.24 (s, 2H). MS 354 (M +). HPLC 16.4 min. (95% H2O: 5% CH3CN) + 0.1% TFA (H20 10%: CH3CN 90%) + 0.1% TFA for 22 min in a Cis Vyadec 218TP54 Column.

Step (g): Preparation of 4- (benzyloxy) -3- [4- (5-bromopentyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarbonitrile To a solution of 4- (benzyloxy) -3- (3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarbonitrile (14) (2g, 5.7 mmol) in DMF (50 ml) was added CS2CO3 (2.21 g, 6.8 mmol) at 0 ° C. The mixture was stirred for 30 min before the addition of 1,5-dibromopentane (4.62 ml, 40.0 mmol). The reaction mixture was stirred overnight, while warming slowly to room temperature, before being added in H2O (100 ml). The aqueous solution was extracted into EtOAc (3x100 ml). The combined organics were washed with brine and dried over MgSO 4. The major compound (15) (1.59g, 53%, Rf = 0.15 15% EtOAc in Hexanes) was isolated by column gradient chromatography (10 to 25% of EtOAc in Hexanes) together with the O-alkylated analogue (1.17 g, 41%, Rf = 0. 31% EtOAc in Hexanes). N-Alkylated: 1 H NMR (400 MHz, CDCl 3) 7.90 (d, 2H); 7.88 (d, 1 H); 7.70 (dd, 1 H); 7.57 (t, 1 H); 7.2-7.4 (m, 6H); 7.03 (d, 1 H); 5.14 (s, 2H); 4.24 (t, 2H); 3.36 (t, 2H); 1.8-1.9 (m, 2H); 1.7-1.8 (m, 2H); 1.5-1.6 (m, 2H). MS 502, 504 (M +). HPLC 23.5 min. (H20 95%: CH3CN 5%) + 0.1% TFA (10% H2O: 90% CH3CN) + 0.1% TFA for 22 min in a Vyadec Column 218TO54.

Step (h): Preparation of 4- (benzyloxy) -3- (4-5 - [(2?, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4 -dihydro-2-quinoxalinyl) benzenecarbonitrile 16 4- (Benzyloxy) -3- [4- (5-bromopentyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarbonyl ether (15) (1.59 g, 3.17 mmol) DMF (5 mL) was dissolved in anhydrous and cis-2,6-d-methylpiperidine (15 mL) was added. The reaction mixture was heated at 75 ° C overnight. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (2x20 mL). The combined organics were washed with brine, dried over MgSO 4 and concentrated to yield light yellow syrup, which was used without further purification (16). 1 H NMR (400 MHz, DMSO) 7.95 (dd, 1 H); 7.93 (d, 1 H); 7.86 (d, 1 H) 7.6-7.7 (m, 2H); 7.2-7.4 (m, 7H); 5.22 (s, 2H); 4.23 (t, 2H), 0.9-2.5 (m 22H). MS 535 (M +). HPLC 18.8 min (95% H2O: 5% CH3CN) + 0.1% TFA (H20 10%: CH3CN 90%) + 0.1% TFA for 22 min in a Cis Vyadec 218TP54 Column.

Step (i): Preparation of 3- (4-5 - [(2?, 6S) -2,6-dimethyltetrahydro-1 (2W) -pyridium-pentyl-3-oxo-3,4) -dihydro-2-quinoxalinyl) -4-hydroxybenzenecarboximidamide 16 17 A solution of 4- (benzyloxy) -3- (4-5 - [(2R, 6S) -2,6-d.methyltetrahydro-1 (2r7) -pyridinyljpentyl-S-oxo-S ^ -dihydro ^ - Crude quinoxalini benzenecarbonitrile (16) (assume 3.17 mmol), in anhydride EtOH (20 ml), at 0 ° C, saturated with HCl (g) HCl (g) bubbled through concentrated H2SO4 before introduction into the mixture The reaction mixture was capped and warmed to room temperature overnight or until HPLC showed the initial material consumption and a maximum point in 16.4 min.The mixture was concentrated in vacuo and used without further purification. The above crude residue was dissolved in NH3 (2M in EtOH, 20 ml) and capped, after stirring for 18 hours at room temperature, HPLC showed the complete consumption of the initial materials and a new maximum point in 15.5 min. The mixture was concentrated and the residue was sent to a laboratory of high pressure for hydrogenation (Pd / C, H2, TFA, 24 h). HPLC showed a new maximum point in 14.3 min. The mixture was concentrated and purified by prep-HPLC (100% H20 + 0.1% TFA in 20% H2O: 80% CH3CN + 0.1% TFA for 140 min) to yield PD 198961 -0121 b. The above lyophilized solid was dissolved in H2O (100 ml) and Amberlite 400 (Cl) resin was added. After stirring for 3 h, the resin was filtered and the aqueous solution was lyophilized. The lyophilized solid was dissolved in MeOH (5 ml) and the product (17) was crystallized by the slow addition of excess EtOAc. Filtration produced 198961 -0002b as a yellow solid (630 mg, 30% bromide). 1 H NMR (400 MHz, DMSO) 9.14 (s, 1 H); 9.00 (s, 1 H); 8.34 (d, 1 H); 7.91 (d, 1 H); 7.81 (dd, 1 H); 7.71 (m, 2H), 7.47 (m, 1 H); 7.11 (d, 1 H); 4.31 (m, 2H); 3.0-3.8 (m, 2H); 1.2-1.8 (m, 20 H), MS 462 (M +). HPLC 14.3 min. (H20 95%: CH3CN 5%) + 0.1% TFA a (H2O 10%: CH3CN 90%) + 0.1% TFA for 22 min in a C18 Column Vyadec 218TO54.

Intermediaries 2- (3-Cyanophenyl) -3,4-dihydro-2H-1,4-benzoxazin-3-one Step (a): Preparation of 2 - [(3-Cyanophenyl) methylene] malonitrile II 12 In a mixture of 3-cyanobenaldehyde (11) (24.8 g, 0.189 mmol) and malon'tril (11.9 ml, 0.189 mol) in dioxane (120 ml) was added piperidine (1.5 ml) slowly. The solution was stirred at room temperature for 1 hour. The precipitate was filtered, washed with water and dried in a high vacuum oven to give 7.11 g (21%) of product (12) as a yellow solid. Ethanol and water were added to the filtrate and 10.29 g (30%) of additional product crystallized as a yellow solid. 1 H NMR (CDCis, 300 MHz): d 8.17 (1 H, m), 8.51 (1 H, m), 7.87 (2 H, m), 7.68 (1 H, m).

Step (b): Preparation of 3- (3-cyanophenyl) -2,2-oxiranodicarbonitrile 12 13 In a 3-neck flask, intermediate (12) (17.38 g, 97.0 mmol) was dissolved in acetonitrile (90 mL) and THF (113 mL) at room temperature with vigorous stirring. Sodium hypochlorite (183 ml) was added dropwise, while the pH of the solution was kept between 4.5 and 6 during the whole addition by adding 2N sulfuric acid (20 ml). Once the addition was complete, stirring was continued for 20 minutes. Ethyl acetate was added and the layers separated. The aqueous layer was extracted with ethyl acetate (3 x 300 ml). The combined organic extracts were washed with brine (2 x 100 ml), dried with magnesium sulfate and evaporated in vacuo. This residue was rinsed as a silica gel pad eluting with 50% ethyl acetate in hexane. The product (13) was isolated 11.18 g (58%) as a light brown solid. 1 H NMR (CDCb, 300 MHz): d 7.83 (1 H, m), 7.76 (1 H, m), 7.67 (2 H, m), 4.78 (1 H, s).

Step (c): Preparation of 2-Bromo-2- (3-cyanophenyl) acetic acid 13 14 To the epoxide (13) (5.12 g, 62.2 mmol) in THF (30 ml) was added 48% HBr (4.4 ml) and the solution was refluxed for 3 hours. The THF was removed in vacuo and the residue was dissolved in ether (200 ml). The acid was extracted from the ether with 1 N NaOH (100 ml). The aqueous solution was subsequently acidified with HCl and the acid was extracted with ether (2 x 200 ml). The combined organic phases were dried over magnesium sulfate, filtered, evaporated in vacuo and dried under high vacuum to give 4.32 g (69%) of (14) as a brown oil. 1 H NMR (CDCl 3, 300 MHz): d 7.83 (1 H, m), 7.73 (1 H, m), 7.55 (1 H, m), 7.41 (1 H, m), 5.26 (1 H, s).

Step (d): Preparation of 2-Bromo-2- (3-cyanophenyl) acetyl chloride 14 To the acid (14) (1.01 g, 4.21 mmol) in dichloromethane (12 ml) was added oxalyl chloride (1 equiv.) And a catalytic amount of DMF (0.1 ml). The bubbling occurred and the resulting solution was stirred for 1 hour. The solvent was removed in vacuo to give (15) in quantitative product as a brown oil. 1 H NMR (CDCl 3, 300 MHz): d 7.80-7.72 (3H, m), 7.592 (1 H, m), 5.64 (1 H, s).

Procedure for preparing Methyl 2-bromo-2- (3-bromophenyl) acetate To 3-bromophene-acetic acid (16) (10 g, 47 mmol) under argon was added PBr3 (11.2 mL, 118 mmol) and the suspension was stirred at room temperature for 45 minutes. Bromine, (11.1 ml, 216 mmol) was added dropwise over 5 minutes. The mixture was stirred at 100 ° C for 3 hours and then cooled. Anhydride methanol (35 ml) was added dropwise over 30 minutes and subsequently the reaction mixture was diluted with ether (400 ml), washed with 5% NaHCO3 (800 ml), brine (200 ml) and then dried over MgSO4- The mixture was filtered and concentrated in vacuo to provide material of sufficient purity (17) for direct use.

Procedure for preparing (3S) -3-benzyl-3,4-dihydro-2 (7H) -quinoxalinone 18 19 A-ortho-fluoronitrobenzene (18) (6.5 g, 46 mmol) in ethanol (200 ml) and water (200 ml) under nitrogen was added L-phenylalanine (5.10 g, 31 mmol) and sodium bicarbonate (5.19 g, 62 mmol) and the suspension was heated to reflux for 48 h. The red solution was cooled, extracted with ether (2 x 50 ml) to remove any unreacted ortho-fluoronitrobenzene and concentrated to Vz volume, Pd / C (20%, 0.5 g) was added and a hydrogen balloon was added. After stirring overnight, the mixture was filtered, acidified with 1 N HCl to pH 4 and the solid formed was collected, which was dried under high vacuum to provide the main compound (4.66 g, 53%) of purity enough (19) to be used directly.

Procedure for preparing 3-benzyl-2 (yY) -quinoxalinone A (3S) -3-benzyl-3,4-dihydro-2 (7-r7) -quinoxalinone (19) (4.66 g, 19.6 mmol) as a suspension in toluene (200 ml) was added DDQ (4.45 g, 1 equiv. ) and the mixture was stirred at room temperature overnight. The gray solid was collected by filtration and crystallized from ethanol / water to yield the required compound (110) (3.02 g, 65%). 1 H NMR (DMSO, 400 MHz): d 12.35 (1 H, s), 7.67 (1 H, d, J = 8.1 Hz), 7.44 (1 H, t, J = 7.8 Hz), 7.3-7.15 (7H, m), 4.08 (2H, s).

The compounds of the invention have demonstrated the inhibitory activity of factor Xa, thrombin and factor Vlla in the standard tests commonly employed by those skilled in the art.

Determination of Factor Xa IC50 and Constants K1 The ability of compounds to act as inhibitors of the catalytic activity of human factor Xa is indicated by determining the concentration of the test substance that inhibits 50% (IC50) ability of human factor Xa to penetrate the chromogenic substrate S2765 (N-CBz-D-Arg-L-Gly-L-Arg-p-nitroaniline, 2HCI, DiaPharma). Typically, 145 μl human factor Xa (1 nM final, Enzyme Research Laboratories) in 10 mM HEPES, 150 nM NaCl, 0.1% BSA, pH 7.4 (HBSA stabilizer) and 5 μl of the test substance in DMSO (2% final ) were incubated for 60 minutes at room temperature. Following preheating at 37 ° C for 5 minutes, 100 μl of S2765 in HBSA stabilizer was added to this mixture. The hydrolysis rate of S2765 was determined at 37 ° C by measuring the initial rate of change of optical density at OD405 nM every 10 seconds for 5 minutes using a Kinetic Microplate Reader ThermoMax®. For the determinations K ,, the test conditions were essentially the same as the previous ones except for the following. The concentration of factor Xa was 50 pM and that the substrate, in this case a fluorogenic S2765 (for example, S2765 labeled AMC instead of pNA, California Peptide Research), was in the range of 10 to 500 μM. The test compound and substrate in HBSA stabilizer were incubated as indicated above and the reaction was started with enzyme stabilizer. The information (velocity status at various substrate concentrations and inhibitors) of the competitive inhibition was analyzed using the methods described by Segel (Enzyme Kinetics, Wiley Interscience Publications, 1993). A non-linear regression program, Kaleidograph and / or Microsoft Excel, was used to estimate the kinetic parameters (Km, Vmax and K¡) by using Michaelis-Menten and the reciprocal settings of the Dixon diagram.

Determination of Thrombin IC50 and K2 Constants The ability of compounds to act as inhibitors of the catalytic activity of human thrombin is indicated by the determination that the concentration of the test substance that inhibits by 50% (IC50) the ability of human thrombin to penetrate the chromogenic substrate Chromozine TH (Tosyl-Gly-Pro-Arg-pNA * Ac, Boehringer Mannheim). Typically, 145 μl of human thrombin (0.75 nM, Enzyme Research Laboratories) in an HPB stabilizer (10 mM HEPES, 100 mM NaCl, 0.05% BSA, 0.1% PEG-8000, pH 7.4) and 5 μl of the test substance in DMSO (final 2%) were incubated for 60 minutes at room temperature. Following preheating at 37 ° C for 5 minutes, 100 μl of Chromozyme TH in HPB stabilizer was added to this mixture. The hydrolysis rate of Chromozyme THF was determined at 37 ° C by measuring the initial rate of change of optical density at OD405 nM every 10 seconds for 5 minutes using a Kinetic Microplate Reader ThermoMax®.

For determinations K, the test conditions were essentially the same as those already mentioned except for the following. The concentration of thrombin used was 50 pM and that a fluorogenic TH-Chromozyme (for example, Chromozyme TH with AMC instead of the pNA label, Novabiochem) was in the range of 1 to 40 μM. The test compound and the substrate in HPB stabilizer were incubated as stated above and the reaction was started with stabilizer-enzyme and run at 24 ° C. The kinetic analysis was performed in a manner similar to that of the factor Xa Xa determinations.

Determination of Trypsin IC50 and K-Constants, The ability of compounds to act as inhibitors of the catalytic activity of human trypsin by determining the concentration of the test substance that inhibits by 50% (IC50) the ability of human trypsin to penetrate the chromogenic substrate S2222 (N-Bz-L-lle-L-Glu-L-Gly-L-Arg-p-nitroanilide, HCl, DiaPharma). Typically, 145 μl of human trypsin (0.5 nM final) in 10 mM HEPES, 150 mM NaCl, 0.1% BSA and 5 μl of the test substance in DMSO (final 2%) were incubated for 60 minutes at room temperature. After preheating at 37 ° C for 5 minutes, 100 μl of S2222 in HBSA stabilizer (100 μM final) was added to this mixture and the speed of S2222 hydrolysis was determined at 37 ° C by measuring the optical density in OD405 nM every 10 seconds for 5 minutes using a Kinetic Microplate Reader ThermoMax®. For the K i determinations, the test conditions were essentially the same as those already mentioned except that the reaction was started with enzyme stabilizer and run at 24 ° C using a substrate range of 10 to 500 μM. The kinetic analysis was carried out in a manner similar to the determinations of factor Xa K.

Tissue Factor Determination / Factor Vlla IC5o The ability of the compounds to act as inhibitors of the catalytic activity of the human tissue factor / factor Vlla complex is indicated by the determination that the concentration of the test substance that inhibits in a 50% (IC) the ability of a recombinant human tissue factor / Vlla factor complex to penetrate the chromogenic substrate Spectrozyme Vlla (CH3SO2-D-CHA-Arg-pNA * AcOH, American Diagnostics) Typically, 50 μL of human factor Vlla (Enzyme Research Laboratories) were incubated for 10 minutes as a 1: 1 mixture (of each final 5 nM) with 95 μl of human recombinant tissue factor (America Diagnostics) in a modified HBSA stabilizer (10 mM HEPES, 5 mM CaCl2, BSA 0.1%, pH 8.0) Subsequently, 5 μl of the test substance in DMSO (2% final) were added and incubated for 60 minutes at room temperature, followed by preheating at 37 ° C for 5 minutes, to this mixture 100 μl of Spectrazyme Vlla (500 μM final) was added in modified HBSA and the Spectralzyme Vlla hydrolysis rate was determined at 37 ° C by measuring the optical density in an OD405 nM every 10 seconds over 5 minutes using a Reader Kinetic of ThermoMax® Microplates.

In Vitro Test for Human Prothrombinase This test demonstrated the ability of the test compounds of the invention to inhibit the human prothrombinase complex (PTase) (typically comprising factor Va, human factor Xa, Ca2 + and phospholipid moiety) and thereby penetration Subsequent prothrombin to produce thrombin. For determination of IC50 (PTase) of the compounds of the invention, PTase activity was expressed by thrombin activity. The PTase reaction was performed in 100 μl of the mixture containing PTase (20 μM) PCPS (Avanti Polar Lipids following a modified procedure of Barenholz et al., Biochemistry, 1977; 16: 2806-2810) within a radius of 30:70. , 2.5 nM human factor Va (Enzyme Research Laboratories) and 2.5 p human factor Xa (Enzyme Research Laboratories) in modified HEPES stabilizer (10 mM HEPES, 150mM NaCl, 0.1% PEG-8000, 0.05% BSA, CaCl22. 5 mM, pH 7.4), 3 μM human prothrombin (Enzyme Research Laboratories) and varying concentrations of the test compounds (1 nM to 100 μM in DMSO, 2% final). The reaction was initiated by co-incubation PTase with a test compound for 60 minutes at room temperature, followed by the addition of thrombin for 6 minutes at room temperature. Then, the reaction was warmed by the addition of 100 μl of 20 mM EDTA. The activity of thrombin (product) was subsequently measured in the presence of 50 μl S2238 (final 250 μM, HD-Phe-Pip-Arg-pNA * Ac, DiaPharma) as substrate by measuring the change at 37 ° C in OD405 nM for 5 minutes at 10-second intervals using a Kinetic Microplate Reader ThermoMax®. Example 2 in this test has an IC50 of 0.0015 uM.

Prothrombin Time Determination (PT) Rat, rabbit, dog and human blood (typically 1.8 ml) was collected and added to a sodium citrate solution (3.8%) to produce a 1: 10 dilution. After centrifugation (2000 g for 10 minutes), the blood plasma was stored at -70 ° C to 0 ° C. Conventional prothrombin time (PT) tests were carried out in the presence of various concentrations of the Test compound and the concentration of the test compound required to double the determined coagulation time. Typically, the test compound (50 μl volume of variation concentrations 0.1 μM to 1000 μM) and blood plasma (100 μl volume) were incubated at 37 ° C for 10 minutes and subsequently the tissue thromboplastin, typically Neoplastin, was added. of American Bioproducts with calcium. The fibrin formation and the time required to form a clot was determined using a ST4 Clots Detection System in duplicate. In an ex vivo modification of this test, the drug was administered intravenously or orally to a group of rats or rabbits. Blood samples were collected at various times and the PT coagulation test was performed as described above.

Antithrombotic Model of Arterio-Venous Deviation Stasis In vivo measurements of thrombotic activity were performed in accordance with the procedure of Vogel et al., Tromb. Res., 1989; 54: 399-410. Briefly, the vena cava was exposed, the collateral veins were ligated and the sutures were located freely around the inferior vena cava. These sutures were hermetically ligated after administration of the drug to induce stasis in the ligated portion of the vena cava. After an appropriate time, the thrombus was isolated and weighed. The effect of varying the concentrations of the drug administered intravenously or orally in the thrombus mass reflected antithrombotic activity. Alternatively and in accordance with the procedure of Smith et al., Br.

J. Pharmacol., 1982; 77: 29-38, the right carotid artery and the left jugular artery were exposed and cannulated. A division containing silk threads or compressed cotton, subsequently inserted, which connects the two cannulated veins.

Once the drug has been administered, the division is closed and the thrombus that forms on the foreign surface in the division is removed after a period of time. The weight of the clot then reflects the thrombotic activity.

Arterial Thrombosis Model Carotid Arterial Lesion Model Induced with FeCI3 The injury induced with FeCI3 to the carotid artery in rats was induced according to the method described by Kurz K.D., Main R.W., Sandusky G.E., Thrombosis Research, 1990; 60: 269-280 and Schumacher W.A. et al., J. Pharmacology and Experimental Therapeutics, 1993; 267: 1237-1242. Male Sprangue-Dawley rats (375-410 g) were anesthetized with urethane (1500 mg / kg-ip). The animals were placed on a heating pad at 37 ° C. The carotid artery was exposed through a mid cervical incision. Saturation dissection was carefully used to isolate the carotid vessel vein. Using forceps, the artery was lifted to provide enough clearance to insert two small pieces of polyethylene tubing (PE-205) underneath it. A temperature probe (Physitemp MT23 / 3) was placed between one piece of tubing and the artery. The lesion was induced by topical application in the carotid artery above the temperature probe of a small disc (3 mm diameter) of Whatman No. 1 filter paper previously immersed in a 35% FeCl3 solution. The incision area was covered with aluminum foil to protect the FeCI3 from degradation by light. The temperature of the vein is monitored for 60 minutes after the application of FeC as an indication of blood flow. Changes in vein temperature were recorded in a thermistor (Cole-Palmer Model 08533-41). The time between the application of FeCl3 and the time in which the temperature of the vein decreased abruptly (>; 2.4 ° C) was recorded as the time for occlusion of the vein. The mean occlusion time (MOT), therefore, refers to the occlusion time in animals treated with drugs divided by the control time of occlusion. The inhibitor compounds were given as an IV bolus (0.75 mg / kg) followed immediately by an IV infusion (50 μg / kg / min via the femoral vein). Typically, the compounds of the invention show 50% inhibition of the proteolytic activity of factor Xa on a synthetic substrate in concentrations between 50 μM to 1 nM.

Additional Biological Information of Example 2 In Vitro Diluted Prothrombin Time Test The effects of Example 2 on dPT were evaluated using a plasma pellet of human volunteers. The concentration of the dPT compound that was dependently prolonged and the concentrations that caused 2 times the prolongation of dPT for Example 2 was 0.05 μM, while at a concentration of 0.1 μM there was a 3.2-fold increase in dPT.

The effects in Example 2 on thrombosis and hemostasis have been studied in a model of thrombosis induced by veno-venous deviation in a rabbit. In such a model, a division containing cotton threads was inserted into the abdominal vena cava and the thrombus developed in the division under control conditions. The end points of the experiment are the occlusion time (TTO) and the weight of the thrombus. Example 2 is given in the jugular vein of a rabbit as a simple bolus followed by constant infusion for 140 minutes. Three doses have been tested in a total of 15 rabbits (5 rabbits in each group): 30 μg / kg + 1 μg / kg / min, 60 μg / kg / min and 480 μg / kg + 16 μg / kg / min. The dose-dependent example 2 prolonged the time of occlusion and reduced the net weight of the thrombus. In the highest dose group, the TTO was increased from 17 minutes under control condition to 100 minutes. The net weight of the thrombus was reduced from 50 to 20 mg in that group. Example 2, at the highest dose, prolonged aPTT, PT by 5- and 3.9 times, respectively. The effects of Example 2 on thrombosis and hemostasis have been studied in a model of electrolytic injury in a dog. In this model, the influence event in thrombosis is an electrical current that is applied to the femoral vein (or artery) by applying a direct anodic current (3000 uA) to the intimal surface of the vein in the presence of blood flow. restricted (Goldblatt forceps were placed around the vein). The end points of the experiment are the occlusion time (TTO) and the weight of the thrombus. Example 2 is given as a continuous infusion at rates of 2.5 μg / kg / min, 5 μg / kg / min and 10 μg / kg / min, whose dose dependent prolonged the time of occlusion and reduced the net weight of the thrombus. In the highest dose group, the TTO increased to the closest maximum effect of 240 minutes in both arteries and veins. The net weight of the thrombus was reduced from 50 mg to 18 mg [artery] and 110 mg to 15 mg [vein] in the highest dose group. The effect 2 in the highest dose was prolonged aPTT, PT, by 1.4- and 1.75 times, respectively. The foregoing biological tests have been used to establish that the compounds of this invention are useful for preventing and treating thrombotic diseases, for example, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, cerebral and coronary arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, recurrent or first myocardial infarction, unstable angina and cerebral infarction, attacks, arteriosclerosis. The compounds of the present invention can be administered alone or in combination with one or more therapeutic agents. These include, for example, other anticoagulants, antiplatelets or platelet inhibiting agents including nonsteroidal anti-inflammatory agents such as aspirin, ibuprofen, naproxen sodium, indomethacin, piroxicam and ticlopidine, thrombin inhibitors such as argatroban , efegatran, inogatran, factor Vlla inhibitors, fibrinolytic or thrombolytic agents such as tissue plasminogen activator, urokinase or streptokinase and GP lllblia antagonists. The compounds are therefore well adapted to the formulation for convenient administration to mammals for the prevention and treatment of such diseases. The following additional examples illustrate the typical formulations provided by the invention.

Formulation 1 The above ingredients are mixed and dissolved in the saline solution for IV administration to a human suffering from, for example, arterial thrombosis.

Formulation 2 The ingredients are liquefied to uniformity and compressed into a tablet that is well adapted for oral administration to a human to prevent, for example, cerebral infarction.

Formulation 3 The ingredients are combined and ground to provide appropriate material for filling the hard gelatin capsules administered to humans suffering from, for example, venous thrombosis.

Formulation 4 The ingredients are combined via fusion and then poured into molds containing 2.5 g of total weight.

Formulation 5 The ingredients are dispersed in oleic acid with the impeller. The mixture is added to an aerosol container fitted with a regulating device.

Claims (32)

1. A compound according to Formula I or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein: A is selected from N, Nalkyl, NCH2, N (alkyl) CH2, CH2N, CH2N (alkyl), NO; B is selected from H, (C3-2o) alkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heteroalkylalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, each optionally substituted with Ri and R2; D is selected from H, alkyl (C3-2o), cycloalkyl, heteroalkyl, cycloalkylalkyl, heteroalkylalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, each optionally substituted with Ri and R2; E is absent or selected from O, S, NH; F is selected from N, NCH2, CH2N; G is absent or selected from alkyl, alkyl interrupted by one or more heteroatoms, cycloalkyl, cycloalkyl interrupted by one or more heteroatoms; J is absent or is selected from aryl or heterocycle each optionally substituted with Ri and R2; K is absent or selected from an alkyl, alkyl interrupted by one or more heteroatoms, cycloalkyl interrupted by one or more heteroatoms, cycloalkylalkyl interrupted by one or more heteroatoms, each optionally substituted with Ri and R2. L is selected from H, chloro, fluoro, bromo, iodo, OH, O (alkyl), amine, alkyl, fluoroalkyl, amide, NO2, SH, S (O) n (alkyl), SO3H, alkyl SO3, aldehyde, ketone , Acid, Ester, Urea, Oalkylamide, O-Alkyl Ester, O-Alkyl Acid, Nalkyl Acid, Alkylamine, Alkylamide, Alkyl Ketone, Alkyl Acid, Alkyl Ester, Alkylurea, Nalkylamide, N-alkyl Ester, NC alkyl (= O), aryl NC (= O), cycloalkyl NC (= O ), cycloalkylalkyl NC (= O), alkylaryl NC (= O), R., R2, nitrile; Ri is selected from H, amine, alkylamine, amide, C (= NH) NHNH2, alkyIC (= NH) NHNH2, C (= NH) NHOH, alkylC (= NH) NHOH, NHC (= NH) NH2, alkylNHC (= NH) NH2, C (= S) NH2, alkylC (= S) NH2, C (= NH) alkyl, alkylC (= NH) alkyl, C (= NR3) N (R4) (R5), alkylC (= NR3) N (R4) (R5); R 2 is selected from H, chloro, fluoro, bromo, iodo, OH, Oalkyl, amine, alkylaldehyde, alkylamide, alkyl ester, alkyl ketone, alkyl acid, O-alkylamide, O-alkyl acid, alkyl ester, aminalkyl acid, aminalkylamide, aminalkyl ester, alkyl NC (= 0), aryl NC (= 0), cycloalkyl NC (= 0), alkylaryl NC (= 0), alkylamine, amide, aldehyde, ester, ketone, N02, SH, S (O) n (CMO alkyl), SO3H, alkyl SO3, CHO , acid, alkyl, alkyl C (= NH), C (= NH) NHNH2, alkylC (= NH) NHNH2, C (= NH) NHOH, alkylC (= NH) NHOH, NHC (= NH) NH2, alkylNHC (= NH) NH2, C (= S) NH2, alkylC (= S) NH2, alkylC (= NH) alkyl, C (= NR3) N (R4) (R5) I alkylC (= NR3) N (R4) (R5); R3, R4 and R5 are a hydrogen atom, an alkyl group having 1 to 4 carbon atoms optionally interrupted by a heteroatom or R4 and R5 are linked to form - (CH2) PW- (CH2) q-, wherein p and q are an integer 2 or 3, a certain position in the methylene chain is substituted or unsubstituted by an alkyl group having 1 to 4 carbon atoms, W is a direct bond, -CH2-, -O -, -N (Rβ) - or -S (O) r wherein R 6 is H or alkyl and r is 0 or 1 or 2; n is selected from 0, 1, 2; X, is C or N; X2 is C or N; Xs is C or N; X4 is C or N and - represent an additional optional link when A is N.

2. A compound according to claim 1, wherein the compound is in accordance with Formula II II or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein A, B, E, G, J, K and L are as defined above.

3. A compound according to claim 1, wherein the compound is in accordance with Formula III or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein A is N or Nalkyl and B, G, J, K, L and - are as defined above.

4. A compound according to claim 1, wherein the compound is in accordance with Formula IV IV or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein G, J, K, L, Ri and - are as defined above.

5. A compound according to Formula V M or stereoisomers or pharmaceutically acceptable salts, esters, amides or prodrugs thereof, wherein X, Y, R, R8 and - are as follows: X is selected from (CH2) 5, (CH2) l (CH_) 6, CH2C (= O) NHCH2CH2, CH2CH2NHC (= 0) CH2I (CH2) 2NH (CH2) 2, (CH2) 2O (CH2) 2, CH2C6H4, CßHio, CsHs, C5H8CH2 and CH2CH = CHCH2CH2; Y is selected from 2,6-dimethylpiperidinyl, piperidinyl, 2,2,6,6-tetramethyl-p-peridinyl-4-one, (2-carboxy) piperidinyl, (3-carboxy) piperidinyl, (4-carboxy) piperidinyl 1 3,5-dimethylpiperidinyl, (4-hydroxy) piperidinyl, (2-imino) piperidinyl, piperidin-4-one-yl, (2-dimethylaminomethyl) -piperidinyl, (4-dimethylamino) -piperidinyl, (4-sulfonyloxy) - piperidine, (2-phenyl) piperidinyl, 2,5-dimethylpyridinidinyl, pyrrolidinyl, (2-carboxy) pyrrolidinyl, (3-N-acetyl-N-methyl) pyrrolidinyl, (3-amino) pyrrolidinyl, (2,5-bis-methoxymethyl) -pyridinidinyl, 2-hydroxymethyl-pyrrolidinyl, 2-hydroxymethyl-5-methyl-pyrrolidinyl, diisopropylamino, dimethylamino, diethylamino, methylamino, 1-methyl-4,5-dihydro-1H-imidazole -2-yl, 2,5-dimethyl-1-l-imidazoyl, morpholinyl, 2,6-dimethylmorpholinyl, piperazinyl, 2,6-dimethylpiperazinyl, 1 H-pyrazolyl, tetrahydro-1 H-pyrazolyl and 2,5- dimethyltetrahydro-1 H-1-pyrazolyl; R is selected from (3-amidino) phenyl, (3-hydroxy) phenyl, [3-hydroxylamino (imino) methyl] -phenyl, [3-hydrazino (imino) meth] phenyl, (3-aminomethyl) phenyl, (3-amino) phenyl, (3-methylamino) phenyl, 3-dimethylamino) phenyl, 5-amidino-2-hydroxy) phenyl, 1-amidino) piperid-3-yl, 1-amidino) pyrrolid-3-yl, 5-amidino) thien-2-yl, 5-amidino) furan-2-yl, 5-amidino) -1, 3- oxazol-2-yl, 2-amidino) -1, 3-oxazol-5-yl, H-pyrazol-5-yl, ehydro-1 H -pyrazol-3-yl, 1 -amidino) tetrahydro-1 H -pyrazole -3-yl, 2-amidino) -1 H -imidazoI-4-yl, 2-amino) -1 H -imidazol-4-yl, 5-amidino) -1 H -imidazol-2-yl, 5-amino ) -1 H-imidazol-2-yl, pyridin-3-yl, 4-amino) pyridin-3-yl, 4-dimethylamino) pyridin-3-yl, 6-amino) pyridin-2-yl, 6 -amidino) pyridin-2-yl, 2-amino) pyridin-4-yl, 2-amidino) pyridin-4-yl, 2-amidino) pyrimid-4-yl, 2-amino) pyrimidin-4-yl , (4-amidino) pyrimid-2-yl, (4-amino) pyrimidin-2-yl, (6-amidino) pyrazin-2-1, (6-amino) pyrazin-2-yl, (4-amidino) -1, 3,5-triazin-2-yl, (4-amino) -1. ^ D-triazin-S-il, (3-amidino) -1, 2,4-triazin-5-yl, (3-amino) -1, 2,4-triazin-5-yl, (3-amidino) benzyl, (3-amino) benzyl, (3-aminomethyl) benzyl, (1 -amidino) piperid-3-ylmethyl, (1-amino) -pyrrolid-3-methyl, (5-amidino) thien-2-ylmethyl, (5-amidino) furan-2-ilmetl, (5-amidino) oxazol-2-ylmethyl, (2-amidino) imidazol-5-ylmethyl, (5-amidino) imidazol-2-ylmethyl, (6-amidino) pyridin-2-ylmethyl, (6-amino) pyridin-2-ylmethyl, (2-amidino) pyrimidin-4-ylmethyl, (2-amino) pyrimidin-4-ylmethyl, (4-amidino) pyrimidin-2-ylmethyl, (4-amino) pyrimidin-2-ylmethyl, (6-amidino) pyrazin-2-ylmethyl, (6-amino) pyrazin-2-ylmethyl, 3-aminocyclohexyl, 3-amidinocyclohexyl, 3-aminocyclohexylmethyl, 3-amidinocyclohexylmethyl, 3-aminocyclopentyl, 3-amidinocyclopentyl, 3-aminociclopentylmethyl and 3-amidinocyclopentylmethyl and selected from H, Cl, F, SH, SMe, CF3, CH3, CO2H, CO2Me, CN, C (= NH) NH2, C (= NH) NHOH, C (= NH) NHNH2 , C (= O) NH2, CH2OH, N02, OH, OMe, OCH2Ph, OCH2CO2H, 0 (CH2) 2C02H, O (CH2) 3CO2H, NHCH2CO2H, NH (CH2) 2CO2H, NH (CH2) 3CO2H, OCH2CH2OH, OCH2 (1 H-tetrazol-5-yl), NH2, NHButil, NMe2, NHPh, NHCH2Ph, NHC (= O) Me, NHC (= 0) c-Hexyl, NHC (= 0) CH2c-Hexyl, NHC (= 0) Ph, NHC (= O) CH2Ph, NHS (= 0) 2Me, NHS (= O) 2c-Hexyl, NHS (= O) 2CH2c-Hexyl, NHS (= O) 2Ph and NHS (= O) ) 2CH2Ph.

6. A compound according to claim 5, wherein X is (CH2) s-

7. A compound according to claim 5, wherein Y is 2,5-dimethylpyrrolidinyl.

8. A compound according to claim 5, wherein Y is 2,6-dimethylpiperidinyl.

9. A compound according to claim 5, wherein R is (5-amidino-2-hydroxy).

10. A compound according to claim 5, wherein Rs is H.

1. A compound according to claim 5, wherein X is (CH2) 5, Y is 2,6-dimethylpiperidinyl and Rs is H.

12. A compound which is 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 1 -5 - [(2R; 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3- (3-hydroxyphenyl) -2 (7 - /) - quinoxalinone; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) - / V-hydroxybenzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidohydrazide; 3- [3- (Aminomethyl) phenyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-2 (7 / - /) - quinoxalinone; 3- (3-Aminopheni) -1-5 - [(2R, 6S) -2,6-d.methyltetrahydro-1 (2rY) -pyridinyl] pentyl-2 (7H) -quinoxalinone; 1-5 - [(2R 6S) -2,6-Dimethyltetrahydro-1 (2 7) -pyridinyl] pentyl-3- [3- (methylamino) phenyl] -2 (7H) -quinoxalinone; 3- [3- (Dimethylamino) phenyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 -) -pyridinyl] pentyl-2 (7 / - /) - quinoxalinone; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -4- hydroxybenzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) tetrahydro-1 (2H ) -pyridinecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1- pyrrolidinecarboximidamide; 5- (4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -2-thiophenecarboximidamide; 5- (4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2W) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) - 2-furancarboximidamide; 2- (4-5 - [(2R; 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1, 3-oxazole-5-carboximidamide; 5- (4-5- [2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / t) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1, 3-oxazole -2-carboximidamide; 1-5 [(2Ry6S) -2,6-Dimethyltetrahydro-1 (2ry) -pyridinyl] pentyl-3- (1H-pyrrazol-3-yl) -2 (1 H) -quinoxalinone; 1-5 - [(2R; 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentiol-3-tetrahydro-7-p7-pyrazol-3-yl-2 (7H) -quinoxaIinone; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1-pyrazolidinecarboximidamide; 5- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 7,) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) - 7 - / - imidazole-2-carboximidamide; 3- (2-Amino-7-and-imidazol-5-yl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] penti-2 (7 - /) - quinoxalonone; 2- (4-5 - [(2R 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -7H-imidazole-5-carboximidamide; 3- (5-Amino-1 H-imidazol-2-yl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (7H) -quinoxalinone; 1-5- [2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3- (3-pyridinyl) -2 (yr) -quinaxolinone; 3- (6-Amino-3-pyridinyl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyrridinyl] pentyl-2 (7 - /) - quinoxalinone; 3- [6- (Dimethylamino) -3-pyridinyl] -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyrridinyl] pentyl-2 (7 / - /) - quinoxalinone; 3- (6-Amino-2-pyridinyl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (/?) - quinoxalinone; 6- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -2-pyridinecarboximidamide; 3- (2-Amino-4-pyridinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2r - /) - pyridinyl] pentin-2 (7 - ) -noxalinone; 4- (4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) - 2-pyridinecarboximidamide; 4- (4-5 - [(2R / 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) - 2-pyrimidinecarboxyramide; 3- (2-Amino-4-pyrimidinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2-r7) -pyridinyl] pentyl-2 (7 / - /) - quinoxalinone; 2- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2f - /) - pyridinyl] penti-3-oxo-3,4-dihydro-2 -quinoxalinyl) -4-pyrimidinecarboximidamide; 3- (4-amino-2-pyrimidinyl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] penti-2 ( 7H) -quinoxalonone; 6- (4-5 - [(2R / 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -2-pyrazinecarboximidamide; 3- (6-Amino-2-p -razinyl) -1-5 - [(2R 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (7r) -quinoxalinone; 4- (4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1 I3 , 5-triazine-2-carboximidamide; 3- (4-Amino-1,3,5-triazin-2-yl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl- 2 (7 -) -quinoxalinone; 5- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2A7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -1, 2,4-triazine-3-carboxamidedamide; 3- (3-Amino-1, 2,4-triazin-5-yl) -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentiol 2 (7H) -quinoxalinnone; 3 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] benzenecarboximidamide; 3- (3-Aminobenzyl) -1-5 - [(2R, 6S) -2,6-d.methyltetrahydro-1 (2 - /) - pyridinyl] pentyl-2 (7H) -quinolone; 3- [3-Aminomethyl) benzyl] -1-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (7H) -quinoxalinone; 3 - [(4-5 - [(2R, 6S) -2I6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] tetrahydro-1 (2H- pyridinecarboximidamide; 3 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro- 2- quinoxalinyl) methyl] -1-pyrrolidinecarboxamidamide; 5 - [(4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2r7) -pyridinyl] pent L-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -2-thiophenecarboximidamide; 5 - [(4-5 - [(2R / 6S) -2,6-D'met Ltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -2-furancarboximidamide; 2 - [(4-5 - [(2R, 6S ) -2,6-D-methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -1,3-oxazole-5-carboximidamide; 5 - [( 4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2rt ') - pyridinyl] penti-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -1H- imidazole-2-carboximidamide; 2 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -1 / - / -imidazole-5-carboximidamide; 6 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2W) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxaline l) methyl] -2-pyridinecarboximidamide; 3 - [(6-Amino-2-pyridinyl) methyl] -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] -pentyl-2 (7 ?) - quinoxalinone; 4 - [(4-5 - [(2R; 6S) -2,6-Dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] - 2-pyrimidinecarboximidamide; 3 - [(2-Amino-4-pyridinyl) methyl] -1-5 - [(2R, 6S) -2,6-d.methyltetrahydro-1 (2 - /) - pyridinyl] pentyl -2 (7 / - /) - quinoxalinone; 2 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] -4-pyrimidinecarboximidamide; 3 - [(4-Amino-2-pyrimidinyl) methyl] -1-5 - [(2R / 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1H) -quinoxalinone; 6 - [(4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2r?,) -pyridinium] pentyl-3-oxo-3,4-dihydro-2-quinoxaI nyl) methyl] -2-pyrazinecarboximidamide; 3 - [(6-Amino-2-pyrazinyl) methyl] -1 -5 - [(2R, 6S) -2,6-dithmethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (7 / - /) - quinoxalinone; 3- (3-Aminocyclohexyl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (H) -quinoxalinone; 3- (4-5 - [(2R / 6S) -2,6-D -methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) cyclohexanecarboxim Damida; 3 - [(3-Aminocyclohexyl) methyl] -1-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-2 (7H) -quinoxaIinone; 3 - [(4-5 - [(2R; 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] cyclohexanecarboximidamide; 3- (3-Aminocyclopentyl) -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -. pyridinyl] pentyl-2 (7H) -quinoxalinone; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2f7) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) cyclopentanecarboximidamide; 3 - [(3-Aminocyclopentyl) methyl] -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (7 / - /) - quinoxalinone; 3 - [(4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r) -pyridinyl] pentiol-3-oxo-3,4-dihydro-2-quinoxalinyl) methyl] cyclopentanecarbox midamide; 3- (4-4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] butyl-3-oxo-3,4-dihydro-2-quinoxaliniI) benzenecarboximidamide; 3- (4-6 - [(2R 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] hexyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 2- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2 7) -quinoxalinyl] -? / - 2 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 / -) -pyridinyl] ethylacetamide; 3- [3-3- [Amino (im!) Methyl] phenyl-2-oxo-1 (2H) -quinoxal! Nl] -? / - [(2R / 6S) -2,6-dimethyltetrahydro- 1 (2 - /) - pyridinyl] methylpropanamide; 3-4- [2- (2 - [(2R / 6S) -2,6-Dimethyltetrahydro-1 (2,7) -pyridinyl] et.lamino) ethyl] -3-oxo-3,4-dihydro-2- Quinoxalinylbenzenecarboximidamide; 3- [4- (2-2 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] ethoxyethyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- (4-4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] phenyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] benzyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- [4- (4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] methylphenyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboxamidamide; 3- (4-4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] cyclohexyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- [4- (4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2rY) -pyridinyl] cyclohexylmethyl] -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- [4- (4 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 -) -pyridinyl] methyl-cyclohexyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- (4-3 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] cyclopentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- [4- (3 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2f) -pyridinyl] cyclopentylmethyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- [4- (3 - [(2R, f3S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] methylcyclopentyl) -3-oxo-3,4-dihydro-2-quinoxalin I] benzenecarboximidedamide; 3- (4- (E) -5 - [(2R / 6S) -2,6-Dimethyltetrahydro-1 (2 / L /) - pyridinyl] -2-pentenyl-3-oxo-3,4 -dihydro-2-quinoxalyl) benzenecarboximidamide; 3- [3-Oxo-4- (5-piperidinopentyl) -3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3-3-Oxo-4- [5- (2,2,6,6-tetramethylpiperidino) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 1 -5- [3-3- [Amino (imino) methy1] phenyl-2-oxo-1 (2 -) -cyanoxalinyl] pentyl-2-piperidinecarboxylic acid; 1 -5- [3-3- [Amino (imino) methyl] phenyl] -2-oxo-1 (2H) -quinoxalinyl] pentyl-3-piperidinecarboxylic acid; 1 -5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2H) -quinoxalinyl] pentyl-4-piperidinecarboxylic acid; 3-4- [5- (3,5-Dimethylpiperidino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (4-Hydroxypiperidino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (2-lymnopyridinyl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-3-Oxo-4- [5- (4-oxopiperidino) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [4- (5-2 - [(Dimethylamino) methyl] piperidinopentyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- (4-5- [4- (Dimethylamino) piperidinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; acid-1-5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2 H) -quinoxalinyl] pentyl-4-piperidinesulfonic acid; 3-3-Oxo-4- [5- (2-phenylpiperidino) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (2,5-Dimethyl-1-pyrrolidinyl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-3-Oxo-4- [5- (1-pyrrolidinyl) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 1 -5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2H) -quinoxalinyl] pentyl-2-pyrrolidinecarboxylic acid; ? - (1-5- [3-3- [Amino (imino) methyl] phenyl-2-oxo-1 (2 - /) - quinoxalinyl] pentyltetrahydro-1H-pyrrol-3-yl) -N-methylacetamide; 3-4- [5- (3-Amino-1-pyrrolidinyl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- (4-5- [2,5-bis (Methoxymethyl) -1-pyrrolidinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5- [2- (Hydroxymethyl) -1-pyrrolidinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5- [2- (Hydroxymethyl) -5-methyl-1-pyrrolidinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3-4- [5- (Di¡sopropylammono) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (Diethylamino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (Methylamino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (1 -Methyl-1 r7-imidazol-2-yl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-4- [5- (2,5-Dimethyl-1H-imidazol-1-yl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [4- (5-Morpholinopentyl) -3-oxo-3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3-4- [5- (3,5-Dimethylmorpholino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [3-oxo-4- (5-piperazinopentyl) -3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3-4- [5- (2,6-Dimethyl-piperazino) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3-3-Oxo-4- [5- (1 H -pyrazol-1 -yl) pentyl] -3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- [3-Oxo-4- (5-tetrahydro-1-r7-pyrazol-1-ylpentyl) -3,4-dihydro-2-quinoxalinyl-benzenecarboximidamide; 3-4- [5- (2,5-Dimethyltetrahydro-1H-pyrazol-1-yl) pentyl] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- (6-Chloro-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2rV) -pyridinyl] pentyl-6-fluoro-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarbox Midamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2-r7) -pyridinyl] pentyl-3-oxo-6-sulfanyl-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-6- (methylsulfanyl) -3-oxo-3,4-dihydro -2-quinoxalyl] benzenecarboximidamide; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentyl-3-oxo-6- (trifluoromethyl) -3,4-dihydro-2-quinoxalinyl ] benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (.2H) -pyridinyl] pentyl-6-methyl-3-oxo-3,4-dihydro- 2-quinoxalinyl) benzenecarboximidamide; acid-2-3- [Amino (imin) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentiI-3-oxo-3,4 -dihydro-6-quinoxalinecarboxylic acid; Methyl 2-3- [amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro- 6-quinoxalinecarboxylate; 3- (6-Cyano-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] penti-3-oxo-3,4-dihydro-2 -quinoxalinyl) benzenecarboximidamide; 2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-6 -quinoxalinecarboximidamide; 2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyl-tetrahydro-1 (2 -7) -pyridinyl] pentyl-? -hydroxy-3-oxo-3,4-dihydro-6-quinoxalinecarboximidamide; 3-4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6- [hydrazino (imino) methyl] -3-oxo-3,4- dihydro-2-quinoxalinylbenzenecarboximidamide; 2-3- [Amino (methyl) methyl] phenyl-4-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl-3-oxo- 3,4-dihydro-6-quinoxalinecarboxamide; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2rY) -pyridinyl] pentyl-6- (hydroxymethyl) -3-oxo-3,4-dihydro-2-quinoxalinyl ] benzenecarboximidamide; 3- (6- (Aminomethyl) -4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2r7) -pyridinium] pentiol-3-oxo-3,4-dihydro-2-quinoxalinyl ) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6-nitro-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6-hydroxy-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-D-methyltetrahydro-1 (2r7) -pyridinyl] pentyl-6-methoxy-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboxim Damida; 3- (6- (Benzylloxy) -4-5 - [(2R, 6S) -2I6-d.methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro- 2-quinoxaolinyl) benzenecarboximidamide; acid-2 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3 , 4-dihydro-6-quinoxalinyl) oxy] -acetic; acid-3 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl -3-oxo-3,4-dihydro-6-quinoxalinyl) oxy] -propanoic acid; acid-4 - [(2-3- [amino] (meth) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -p R-dinyl] pentiI-3-oxo-3,4-dihydro-6-quinoxalinyl) oxy] -butane; acid-2 - [(2-3- [Amino (imn) methyl] phenyl-4-5 - [(2R, 6S) -2,6-d] methyltetrahydro-1 (2H) -pyridinyl] pentyl -3-oxo-3,4-dihydro-6-quinoxalinyl) amino] -acetic; acid-3 - [(2-3- [Amino (meth) meth]] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-6-quinoxalinyl) amino] -propane; acid-4 - [(2-3- [Amino (imino) methyl] phenyl-4-5 - [('2R, 6Sy) -2,6-d.methyltetrahydro-1 (2H) -pyridinyl] pentyl-3- oxo-3,4-dihydro-6-quinoxalinyl) amino] -butanoic; 3- [4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6- (2-hydroxyethoxy) -3-oxo-3,4-dihydro-2-quinoxalinyl ] benzenecarboximidamide; 3- [4-5 - [(2R / 6S) -2,6-Dimethyltetrahydro-1 (2rV) -pyridinyl] pentyl-3-oxo-6- (1 - / - 1, 2,3, 4-tetraazol-5-ylmethoxy) -3,4-dihydro-2-quinoxalinyl] benzenecarboximidamide; 3- (6-Amino-4-5 - [(2R, 6S) -2l6-dimethyltetrahydro-1 (2f? ') Pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (6- (Butylamino) -4-5 - [(2R / 6S) -2,6-dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-3,4- dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (6- (Dimethylamino) -4-5 - [(2R / 6S) -2,6-d.methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl ) benzenecarboxylamide; 3- (6-Anilino-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarbox Midamide; 3- (6- (Benzylamino) -4-5 - [(2R 6S) -2,6-dimethyltetrahydro-1 (2rV) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R; 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4 -dihydro-6-quinoxalinyl) acetamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo- 3,4-dihydro-6-quinoxalinyl) cyclohexanecarboxamide; ? - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-d.methyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3, 4-dihydro-6-quinoxalinyl) -2-cyclohexyl acetamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4 -dihydro-6-quinoxalinyl) benzenecarboxamide; ? / - (2-3- [Amino (imino) methyl] phenyl-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4 -dihydro-6-quinoxalinyl) -2-phenylacetamide; 3-4-5 - [(2R / 6S) -2I6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-6 - [(methylsulfonyl) amino] -3-oxo-3,4-dihydro-2-quinoxalinylbenzenecarboximidamide; 3- (6 - [(Cyclohexylsulfonyl) amino] -4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro -2-quinoxalinyl) benzenecarboximidamide; 3- (6 - [(Cyclohexylmethyl) sulfonyl] amino-4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro -2-quinoxalinyl) benzenecarboximidamide; 3-4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 / - /) - pyridinyl] pentyl-3-oxo-6 - [(phenylsulfonyl) amino] -3,4-dihydro- 2-quinoxalinylbenzenecarboxymethyldane or 3- (6 - [(Benzylsulfonyl) amino] -4-5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl- 3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidedamda.

3. A compound that is: 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2 - /) - pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) benzenecarboximidamide; 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2r7) -pyridinyl] pentiol-3-oxo-3,4-dihydro-2-quinoxalinyl) -? - hydroxybenzenecarboxylamide; 3- [3- (Aminomethyl) phenyl] -1 -5 - [(2R, 6S) -2,6-dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-2 (1 - /) - quinoxa! Inone or 3- (4-5 - [(2R, 6S) -2,6-Dimethyltetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-d-hydroxyquinolyl) -4-hydroxybenzenecarboximidamide .

4. A compound which is: 7-Chloro-1- (3-dimethylamino-propyl) -3-phenyl-1 H-quinoxalin-2-one; 7-Chloro-1- (3-dimethylamino-propyl) -3-phenyl-1 H-quinoxalin-2-one; 3- (4-Chloro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 2 (1H) -Quinoxalinone, 7-methoxy-1,3-bis (p-methoxyphenyl); 3- (3-Chloro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 3- (4-Fluoro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1 H-quinoxalin-2-one; 3- (3,4-Dichloro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1 H -quinol-2-one; 1- (2-Diethylamino-ethyl) -4-oxy-3-phenyl-1 H-quinoxalin-2-one; 1- (2-Diethylamino-ethyl) -4-oxy-3-phenyl-1 H-quinoxalin-2-one; 3- (2-Chloro-phenyI) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 3- (4-Bromo-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1H-quinoxalin-2-one; 2 (1 H) -Quinoxalinone, 7-methoxy-1- (p-methoxyphenyl) -3-phenyl; 7-Methoxy-1- (4-methoxy-phenyl) -3- (4-trifluoromethyl-phenyl) -1H-quinoxalin-2-one; 2 (1H) -Quinoxalinone, 1-methyl-3-phenyl-, 4-oxide; 7-Methoxy-1- (4-methoxy-phenyl) -3- (3-trifluoromethyl-phenyl) -1H-quinoxalin-2-one; 7-Methoxy-1- (4-methoxy-phenyl) -3-p-tolyl-1 H-quinoxalin-2-one; 3- (2-Fluoro-phenyl) -7-methoxy-1- (4-methoxy-phenyl) -1 H -quinol-2-one; 1 - . 1- (3-Diethylamino-propyl) -3-phenyl-1 H-quinoxalin-2-one; 7-Hydroxy-1 - (4-hydroxy-phenyl) -3-phenol-1 H-quinoxalin-2-one; 3- (4-Chloro-phenyl) -1-phenyl-1 H-quinoxalin-2-one; 2 (1 H) -Quinoxalinone, 1,3-diphenyl; 1 - [5- (2,6-Dimethyl-piperidin-1-yl) -pentyl] -3-phenyl-1 H-quinoxalin-2-one; 3-. { 4- [5- (2,6-Dimethyl-pyridin-1-yl) -pentyl] -1-methyl-3-oxo-1, 2,3,4-tetrahydro-quinoxalin-2-yl} -N-hydroxy-benzamidine; 3-. { 4- [5- (2,6-Dimethyl-piperidin-1-yl) -pentyl] -3-oxo-3,4-dihydro-quinoxalin-2-yl} -N-hydroxy-benzamide; 3- (3-Amino-1 H -indazol-5-yl) -1 - [5- (2,6-dimethyl-piperidin-1-yl) -pentyl] -1H-quinoxalin-2-one or 2 ( 1 H) -Quinoxalinone, 1 - [2- (diethylamino) ethyl] -3 - [[4- (methoxy) phenyl] methyl].

15. Uri compound which is: 3- (4-5 - [(2R / 6S) -2,6-DimetiItetrahydro-1 (2H) -pyridinyl] pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl) -4 -hydroxybenzenecarboximidamide.

16. A method for the treatment or prophylaxis of thrombotic diseases in a mammal comprising the administration to said mammal of an effective amount of a compound according to claim 1.

17. A method according to claim 16, wherein said disease is venous thrombosis.

18. A method according to claim 16, wherein said disease is arterial thrombosis.

19. A method according to claim 16, wherein said disease is pulmonary embolism.

20. A method according to claim 16, wherein said disease is myocardial infarction.

21. A method according to claim 16, wherein said disease is cerebral infarction.

22. A method according to claim 16, wherein said disease is restenosis.

23. A method according to claim 16, wherein said disease is cancer.

24. A method according to claim 16, wherein said disease is angina.

25. A method according to claim 16, wherein said disease is diabetes.

26. A method according to claim 16, wherein said disease is a heart failure.

27. A method according to claim 16, wherein said disease is atrial fibrillation.

28. A pharmaceutical formulation comprising a compound according to claim 1, mixed with a carrier, diluent or excipient.

29. A pharmaceutical formulation comprising a compound according to claim 2 together with a carrier, diluent or excipient.

30. A pharmaceutical formulation comprising a compound according to claim 12 together with a carrier, diluent or excipient.

31. A method for inhibiting serine proteases comprising administering to a mammal an effective amount of the serine protease inhibitor according to claim 1.

32. A method according to claim 31, wherein said serine protease is factor Xa.